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Diabetes-associated complications, such as retinopathy, nephropathy, cardiomyopathy, and atherosclerosis, the main consequences
of long-term hyperglycemia, often lead to organ dysfunction, disability, and increased mortality. A common denominator of these
complications is the myofibroblast-driven excessive deposition of extracellular matrix proteins. Although fibroblast appears to be
the primary source of myofibroblasts, other cells, including endothelial cells, can generate myofibroblasts through a process known
as endothelial to mesenchymal transition (EndMT). During EndMT, endothelial cells lose their typical phenotype to acquire
mesenchymal features, characterized by the development of invasive and migratory abilities as well as the expression of typical
mesenchymal products such as α‐smooth muscle actin and type I collagen. EndMT is involved in many chronic and fibrotic diseases
and appears to be regulated by complex molecular mechanisms and different signaling pathways. Recent evidence suggests that
small RNAs, in particular microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are crucial mediators of EndMT. Furthermore,
EndMT and miRNAs are both affected by oxidative stress, another key player in the pathophysiology of diabetic fibrotic
complications. In this review, we provide an overview of the primary redox signals underpinning the diabetic-associated fibrotic
process. Then, we discuss the current knowledge on the role of small RNAs in the regulation of EndMT in diabetic retinopathy,
nephropathy, cardiomyopathy, and atherosclerosis and highlight potential links between oxidative stress and the dyad small
RNAs-EndMT in driving these pathological states.
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Diabetes-associated complications, such as retinopathy, nephropathy, cardiomyopathy, and 30 
atherosclerosis, the main consequences of long-term hyperglycemia, often lead to organ 31 
dysfunction, disability, and increased mortality. A common denominator of these complications is 32 
the myofibroblast-driven excessive deposition of extracellular matrix proteins. Although fibroblast 33 
appears to be the primary source of myofibroblasts, other cells, including endothelial cells, can 34 
generate myofibroblasts through a process known as endothelial to mesenchymal transition 35 
(EndMT). During EndMT, endothelial cells lose their typical phenotype to acquire mesenchymal 36 
features, characterized by the development of invasive and migratory abilities as well as the 37 
expression of typical mesenchymal products such as α-smooth muscle actin and type I collagen. 38 
EndMT is involved in many chronic and fibrotic diseases and appears to be regulated by complex 39 
molecular mechanisms and different signaling pathways. Recent evidence suggests that small 40 
RNAs, in particular microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are crucial 41 
mediators of EndMT. Furthermore, EndMT and miRNAs are both affected by oxidative stress, 42 
another key player in the pathophysiology of diabetic fibrotic complications. In this review, we 43 
provide an overview of the primary redox signals underpinning the diabetic-associated fibrotic 44 
process. Then, we discuss the current knowledge on the role of small RNAs in the regulation of 45 
EndMT in diabetic retinopathy, nephropathy, cardiomyopathy, and atherosclerosis and highlight 46 
potential links between oxidative stress and the dyad small RNAs-EndMT in driving these 47 










Diabetes mellitus (DM) is one of the most common chronic diseases worldwide (1). A prediction 56 
study estimated a significant further increase in the number of people suffering from diabetes, 57 
especially in developing countries, with a global prevalence of 7.7% (439 million adults) by 2030 58 
(1, 2). Long-term hyperglycemia is the main driver of the onset and the progression of common 59 
diabetic complications, particularly those affecting the eye, kidney, nervous system, and 60 
cardiovascular system (3). Such complications are secondary to structural and functional 61 
alterations of organs and tissues that are caused by an increased cellular glucose uptake (4). This 62 
activates inflammatory pathways which ultimately leads to excessive deposition of extra cellular 63 
matrix (ECM) proteins and consequent thickening of the vessel wall (4, 5). Tissue fibrosis is 64 
therefore the common denominator of most diabetic complications, including atherosclerosis, 65 
cardiomyopathy, nephropathy and retinopathy (6). Myofibroblasts are the key mediators of 66 
pathological ECM accumulation (7). These cells are normally involved in tissue repair and are 67 
subsequently removed by apoptosis at the end of the repair process. However, under pathological 68 
situations, their unrestrained activation leads to excessive ECM deposition (8). Myofibroblasts 69 
originate from different precursor cells, depending on the organ and the type of initial injury (9). 70 
Although fibroblasts represent the primary source of myofibroblasts, the latter can also originate 71 
from the inresident or bone marrow-derived mesenchymal cells as well as epithelial and 72 
endothelial cells (ECs), through a process known as epithelial/endothelial to mesenchymal 73 
transition (7, 8). In particular, endothelial to mesenchymal transition (EndMT), the process 74 
involving ECs, is emerging as an important player in the pathogenesis of diabetic fibrosis (10-12). 75 
ECs, constituting the inner layer of blood vessels, are responsible for maintaining vascular 76 
homeostasis in response to endogenous and exogenous perturbations (13, 14). There is good 77 
evidence that ECs, when exposed to hyperglycemia, undergo significant alterations that result in 78 
an imbalance between vasodilation and vasoconstriction as well as the development of 79 
inflammatory and vascular complications (15, 16). Moreover, high glucose concentrations have 80 
been shown to trigger the shift of the endothelium toward the mesenchymal phenotype (17, 18). 81 
Overall, EndMT appears to represent the key link in the interaction between inflammation and 82 
endothelial dysfunction in diabetic complications (19, 20). In the setting of EndMT, ECs lose their 83 
typical cobblestone morphology and tight junctions and acquire increased motility and the ability 84 
to secrete ECM proteins (21). In addition, concurrently with the loss of typical endothelial markers, 85 
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such as vascular endothelial cadherin (VE-cadherin), platelet endothelial cell adhesion molecule 86 
(PECAM-1), also known as CD31, and von Willebrand Factor (vWF), they acquire the ability to 87 
express several mesenchymal markers, such as alpha-smooth muscle actin (α-SMA), smooth 88 
muscle protein 22 alpha (SM22α), fibronectin, vimentin, and fibroblast specific protein-1 (FSP-1) 89 
(21, 22). EndMT is involved in many chronic and fibrotic disease states and appears to be regulated 90 
by several factors (23-25). In diabetes, oxidative stress is emerging as an important trigger of the 91 
ECs transformation into myofibroblasts and vascular remodeling (25, 26). Indeed, hyperglycemia 92 
can increase the production of reactive oxygen species (ROS), which in turn activate signaling 93 
pathways leading to the disruption of ECs hemostasis (27-30). Several signaling pathways have 94 
been demonstrated to be involved in EndMT regulation, e.g., transforming growth factor-beta 95 
(TGF-β) signaling, Notch signaling, fibroblast growth factor/fibroblast growth factor receptor 1 96 
(FGF/FGFR1) signaling pathway, Smad2/3-mediated pathways (31) and pro-inflammatory 97 
signaling cascades (32, 33). An important role in the regulation of EndMT is also played by micro 98 
RNAs (miRNAs), a class of short endogenous non‐coding RNAs that regulate gene expression at 99 
post-transcriptional level by binding to the 3′-untranslated region of messenger RNA (mRNA) (34, 100 
35). A single miRNA can target multiple mRNAs, thus influencing several processes such as cell 101 
differentiation, proliferation, and apoptosis (36). miRNAs can also target significant parts of 102 
pathways since miRNAs with similar (seed) sequence target similar sets of genes and thus similar 103 
sets of pathways (37). Moreover miRNAs can, either positively or negatively, regulate gene 104 
expression (38). As a result, they represent promising markers and druggable targets for many 105 
diseases, including diabetes (39-41). An increasing amount of evidence also suggests that diabetes 106 
progression is linked to the alteration of miRNAs expression profiles; indeed, profibrotic miRNAs, 107 
such as miR-125b, let-7c, let-7g, miR-21, miR-30b and miR-195 have been shown to be 108 
upregulated in EndMT. By contrast, antifibrotic miRNAs, such as miR-122a, miR-127, miR-196 109 
and miR-375, with inhibitory action toward genes responsible for EndMT, have been shown to be 110 
downregulated (42-44). In addition to miRNAs, recent studies have also demonstrated the 111 
involvement of another class of small RNAs, known as long non coding RNAs (lncRNAs), in 112 
diabetes-associated EndMT (45, 46). Compared to miRNAs, the concentrations of lncRNAs are 113 
almost tenfold lower, with the latter exhibiting significant tissue and cell specificity (47). However, 114 
the knowledge of the function and the regulation of lncRNAs are still limited. This review aims to 115 
summarize and discuss the available knowledge on the role of small RNAs in the regulation of 116 
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EndMT in diabetes-associated fibrotic complications such as retinopathy, nephropathy, 117 
cardiomyopathy, atherosclerosis, and its potential link with oxidative. 118 
 119 
Diabetic nephropathy 120 
Diabetic nephropathy (DN) is the leading cause of chronic kidney disease in about 40% of patients 121 
with type 1 and type 2 diabetes (48). Poorly controlled blood glucose concentrations can damage 122 
the filtering functionality of the kidneys, which become unable to remove waste products and extra 123 
fluids from the body (49, 50). The symptoms of DN do not generally manifest in the early stages, 124 
but rather when kidney function has significantly deteriorated (51). Therefore, a tight blood 125 
glucose control is key to prevent the onset and progression of DN (50, 52). The progression of DN 126 
is defined by various clinical stages which reflect the gradual involvement of tissue damage to 127 
different kidney compartments: glomerulus, tubules, vasculature and interstitium (53). The final 128 
stage of DN is characterized by renal fibrosis and organ failure, which are the result of the 129 
excessive accumulation of ECM (54). Renal fibrosis is driven by multiple mechanisms, including 130 
glucose metabolism abnormalities associated with oxidative stress, inflammatory processes, and 131 
hemodynamic changes (55). Consequently, many signaling pathways and cell types (mesangial 132 
cells, endothelial cells and podocytes) are involved in the fibrotic process (56, 57). As mentioned 133 
above, alterations of glucose metabolism not only activate various signaling pathways, (56, 57) 134 
but also induce oxidative stress, a key pathophysiological step in the onset and progression of 135 
diabetes-associated vascular complications (58-60). Indeed, high glucose concentrations activate 136 
the diacylglycerol-protein kinase C (DAG-PKC) pathway, which is associated with endothelial 137 
dysfunction, increased production of extracellular matrix and activation of cytokines and 138 
transforming growth factor-β (TGF-β) (61, 62). In addition, protein kinase C (PKC) induces 139 
oxidative stress by activating mitochondrial NADPH oxidase (18, 63). Increased glucose can also 140 
activate aldose reductase and the polyol pathway, leading to the depletion of Nicotinamide 141 
Adenine Dinucleotide Phosphate (NADPH), which is also required for the generation of the 142 
cellular antioxidant nitric oxide (NO) (64-67). The reduced NO availability compromises the 143 
balance between reactive oxygen species (ROS) generation and antioxidant defense, one of the 144 
leading causes of endothelial dysfunction (68). Furthermore, hyperglycemia enhances the 145 
formation of advanced glycation end products (AGEs), proteins or lipids that become glycated as 146 
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a result of exposure to sugars (69). AGEs increase ROS production and promote inflammation and 147 
fibrosis through the activation of PKC, the nuclear factor kappa light chain enhancer of activated 148 
B cells (NF-kB) and TGF-β, (56, 70). Within the hemodynamic factors driving renal fibrosis, an 149 
important role is played by the over-activation of the renin-angiotensin-aldosterone system 150 
(RAAS), a crucial hormone system in blood pressure regulation and fluid balance (71, 72). 151 
Hyperglycemia and insulin resistance increases the release of angiotensin II (Ang II) a potent 152 
vasoconstrictor belonging to the RAAS system (72-74). Angiotensin II plays an important role in 153 
renal fibrosis by activating a number of factors responsible for ECM production such as TGF-β, 154 
PKC and NF-κB (56, 57). On the other hand, Angiotensin-converting enzyme2 (ACE2), the main 155 
modulator of the RAAS system (72), prevents the accumulation of Ang II by catalyzing the 156 
conversion of Ang II into the vasodilator Angiotensin I (Ang I) (74, 75). Although no cure is 157 
available for DN, the control of blood sugar levels and blood pressure, together with a healthy 158 
lifestyle, can slow or stop its progression. The most common DN treatments are based on the 159 
RAAS system inactivation; precisely with the use of either the ACE inhibitors (ACEis) or 160 
angiotensin receptor blockers (ARBs) or their combination (76, 77). This type of treatments allows 161 
the lowering of proteinuria and the blood pressure within the glomerular capillaries. In addition, 162 
ACEis can also ameliorates kidney fibrosis in combination with other drugs. Is this the case of N-163 
acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) an antifibrotic peptide that, in combination with the 164 
ACEi, imidapril, improves kidney fibrosis restoring antifibrotic miRNAs, such as miR-29 and 165 
miR-let-7 and increasing the inhibition of the profibrotic dipeptidyl peptidase-4 (DPP-4) (78, 79). 166 
DPP-4 inhibitors are another class of medicines used for DN's treatment. In this context, due to the 167 
highest affinity for DPP-4, the drug Linagliptin is one of the most widely used (80). In addition, 168 
promising data also come from treatments aiming at restoring Sirtuin 3 (SIRT3), which appear to 169 
ameliorate renal damage, via inhibition of aberrant glycolysis and preserving mitochondrial 170 
homeostasis (81, 82)  171 
 172 
miRNAs regulation of DN-associated EndMT 173 
The ECM is a three-dimensional network of macromolecules (proteoglycans and fibrous proteins), 174 
present in all tissues and organs, that contributes to tissue morphogenesis, differentiation and 175 
homeostasis. Collagens, elastins, fibronectins and laminins are the main proteins constituting the 176 
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ECM (83, 84). The excessive deposition of ECM components is the hallmark of fibrosis, which 177 
represents a key pathophysiological step in many chronic inflammatory diseases, including 178 
diabetes (85). Myofibroblasts are the main cellular mediators of fibrosis as they have the ability to 179 
invade the interstitial space and produce excessive amounts of ECM proteins (86). Although 180 
resident mesenchymal cells are the main source of myofibroblasts, the latter can also derive from 181 
other type of cells including pericytes, fibrocytes, epithelial and endothelial cells (ECs). The 182 
process involving ECs, known as EndMT, has been shown to actively contribute to the progression 183 
of renal fibrosis (87-89). Besides, the mesenchymal shift contribution to kidney fibrosis can also 184 
be accelerate by the crosstalk between endothelium and epithelium, since EndMT can influence 185 
and induce EMT in tubular cells (90). In this context, N-acetyl-seryl-aspartyl-lysyl-proline 186 
(AcSDKP) plays a crucial role in inhibiting both EndMT and EndMT-mediated EMT. Its 187 
inhibitory action is exerted by targeting the fibroblast growth factor receptor 1 (FGFR1), an 188 
antifibrotic endothelial receptor (90), and by controlling the metabolic switch between glucose and 189 
fatty acid metabolism. Indeed, defects in normal kidney metabolism can accelerate EndMT and 190 
EndMT-mediated EMT contributing to kidney fibrosis (81, 91). An increasing body of evidence 191 
suggests that miRNAs are key regulators of EndMT as they appear differentially expressed under 192 
fibrotic stimuli such as high glucose, TGFβ, and hypoxia (92). This differential expression also 193 
reflects the specific role, profibrotic or antifibrotic, played by miRNAs (44, 93). The most potent 194 
inducer of kidney fibrosis is TGF-β (94) (95), which can trigger EndMT either by activation of 195 
specific signaling pathways, such as Akt and Smad (94, 95), or by increasing the expression of 196 
pro-fibrotic miRNAs (44). In this context, TGF-β mediates EndMT through the up-regulation of 197 
miR-21, a key modulator of fibrosis (11, 96). Specifically, TGF-β elicits miR-21 increase through 198 
the activation of Smad3 which regulates miR-21 expression both at a transcriptional and a post-199 
transcriptional level (97). In addition, Smad3 modulates the expression of other miRNAs and 200 
activates the expression of various fibrotic genes (98). Another mechanism used by miR-21 to 201 
stimulate renal fibrosis is the inhibition of Smad7 protein, a negative regulator of TGF-β1/Smad3 202 
signaling. In this context, Smad7 has been shown to suppress renal fibrosis by down-regulating 203 
pro-fibrotic miRNAs such as miR-21 and miR-192 while up-regulating the anti-fibrotic miR-29b 204 
(98, 99). Additionally, miR-21 also regulates TGF-β-mediated EndMT through the PTEN/Akt 205 
pathway (100). Specifically, TGF-β increases the endothelial expression of miR-21, which in turn 206 
decreases the expression of PTEN, ultimately promoting EndMT by Akt activation. (100-102). 207 
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Another molecule linked to TGF-β signaling in kidney fibrosis is the dipeptidyl peptidase-4 (DDP-208 
4), a multi-functional protein expressed on the surface of most cell types, including ECs (103). 209 
DPP-4 overexpression induces TGF-β-mediated EndMT in diabetic nephropathy (104, 105). 210 
Furthermore, recent studies have reported a relationship between DPP-4 and miR-29 in diabetic 211 
kidney fibrosis, where the overexpression of DPP-4 results associated with the suppression of miR-212 
29s family anti-fibrotic activity (106, 107). In line with these observations, the use of the DPP-4 213 
inhibitor, linagliptin, ameliorates kidney fibrosis by restoring miR-29s and consequentially 214 
inhibiting EndMT in diabetic mice (108). The anti-fibrotic peptide, AcSDKP which suppresses the 215 
TGF-β-induced EndMT in diabetic kidney (109, 110) can also, alone or in combination with 216 
angiotensin-converting enzyme inhibitor (ACEi), ameliorates renal fibrosis by suppressing DPP-217 
4 and restoring the anti-fibrotic miR-29s and miR-let-7s expression in TGF-β-induced EndMT 218 
(79). The crosstalk between miR-29s and miR-let-7s is crucial for maintaining endothelial cell 219 
homeostasis and AcSDKP potentiates this crosstalk regulation (44). Indeed, the presence of 220 
AcSDKP upregulates the antifibrotic miR-let-7 families, especially miR-let-7b, which suppress 221 
TGFβR1 and TGFβ signaling (111). Suppression of TGFβ signaling results in the up-regulation of 222 
the miR-29 family expression, which in turn induce FGFR1 phosphorylation, a critical step for 223 
miR-let-7 production (44, 111). The associated expression of miR-29 and miR-let-7 is also 224 
regulated by an alternative mechanism involving interferon-gamma (IFNγ) (44). Precisely, miR-225 
29 target the profibrotic IFNγ (112) blocking its inhibitory action toward FGFR1 which in turn 226 
induces the expression of miR-let-7 (44, 113). Although not strictly related to DN, an additional 227 
anti-fibrotic mechanism, occurring by the suppression of DPP‐4, involves miR‐448‐3p. EndMT 228 
inhibition and amelioration of vascular dysfunction has been indeed observed in both diabetic mice 229 
and cell models overexpressing miR‐448‐3p (114). A further regulatory mechanism of EndMT in 230 
diabetic nephropathy involves miR-497 and its two targets, ROCK1 and ROCK2, which belong to 231 
the rho-associated kinases (ROCKs) family and are activated in diabetes (115-117). A recent study 232 
showed that ROCKs inhibition, following treatment with melatonin (N-acetyl-5-233 
methoxytryptamine), suppressed TGF-β2-induced EndMT. Specifically, the negative modulation 234 
of ROCK1 and ROCK2 is associated with the melatonin-induced up-regulation of miR-497, both 235 
in glomerular cells and diabetic rats (115). See figures and associated tables to overview of the 236 
signaling pathways involving both anti-fibrotic (Figure 1, Table 1) and pro-fibrotic (Figure 2, 237 




Diabetic cardiomyopathy 240 
Diabetic cardiomyopathy (DCM), another common complication in diabetes, refers to myocardial 241 
dysfunction in the absence of conventional cardiovascular complications (coronary artery disease, 242 
valvular disease) and risk factors (hypertension, dyslipidemia) (118, 119). In the early stages, 243 
DCM is usually asymptomatic and characterized by left ventricular (LV) hypertrophy, LV diastolic 244 
dysfunction with diastolic filling abnormalities, myocardial fibrosis and cell signaling 245 
abnormalities. Disease progression leads to systolic dysfunction (left ventricular low ejection 246 
fraction) accompanied by heart failure, which is characterized by marked hypertrophy and fibrosis 247 
in the advanced stages (118-120). Hyperglycemia, insulin resistance, lipid metabolism defects and 248 
oxidative stress up-regulate the production of advanced glycation end-products (AGEs) and Ang 249 
II, which in turn induce mitochondrial dysfunction in cardiomyocytes and ECs (121-124). 250 
Mitochondrial dysfunction, as well as the Ang II-induced NADPH oxidases stimulation, increases 251 
ROS production and oxidative stress (124, 125). Additionally, oxidative stress is also increased by 252 
lipid accumulation caused by an insulin resistance-induced cardiomyocytes metabolic shift. 253 
Indeed, the increased intake of fatty acid is not adequately metabolized by β-oxidation resulting in 254 
lipotoxicity (118, 120). Oxidative stress can in turn trigger endoplasmic reticulum (ER) stress, 255 
impairment of mitochondrial Ca2+ uptake, cardiomyocyte hypertrophy, ECs damage, 256 
microvascular dysfunction and the profibrotic responses by fibroblasts and inflammatory cells 257 
(118, 120). All these effects contribute to the accumulation of ECM, especially collagen type I and 258 
III, leading to myocardial fibrosis (119, 126). The main signaling pathways underlying these 259 
pathophysiological events include TGFβ/SMAD, NFκB/SMAD, PKC, MAPK, Wnt/β-catenin, 260 
Notch2 and AcSDKP-FGFR1 signaling pathway (90, 127-131). Most of these pathways lead to 261 
the development of cardiac fibrosis through the differentiation of fibroblasts into myofibroblasts 262 
as well as the endothelial-to-mesenchymal or epithelial-to-mesenchymal transition (132). 263 
Furthermore, increasing evidence suggests that miRNAs are the main players in the regulation of 264 
multiple pathways and cellular processes leading to cardiac fibrosis (130, 133, 134). 265 
 266 
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miRNAs regulation of DCM-associated EndMT 267 
The hyperglycemia-induced ECs damage and activation, resulting in vascular remodeling and 268 
EndMT, has been confirmed in myocardial fibrosis (135). As suggested by experimental evidence, 269 
cardiac fibrogenesis involves the presence of a subset of EndMT-derived activated cardiac 270 
fibroblasts (135-137). Similarly, miRNAs are an important regulatory mechanism in cardiac 271 
fibrosis and heart failure (138, 139). In this context, miR-21, which has been widely described in 272 
pulmonary and renal fibrosis (140), plays an important role also in the pathogenesis of cardiac 273 
fibrosis and diabetic cardiomyopathy (133, 141-143). A recent in vivo study confirmed the 274 
involvement of miR‐21 in EndMT activation and myocardial fibrosis, showing that the 275 
hyperglycemia-induced up-regulation of miR‐21 in diabetic mice is associated with the down-276 
regulation of endothelial markers and the up-regulation of fibroblast markers (144). Moreover, 277 
similarly to the mechanism described in diabetic nephropathy (97), miR-21 regulates EndMT 278 
through the NF‐κB-SMAD signaling pathway by targeting SMAD7. The consequent SMAD7 279 
inhibition increases SMAD2 and SMAD3 phosphorylation, resulting in EndMT activation (144). 280 
An additional mechanism, requiring the TGF-β/SMAD pathway, involves miR-142-3p, which has 281 
been shown to attenuate the hyperglycemia-induced EndMT in human aortic endothelial cells 282 
(HAECs) (145). Indeed, miR-142-3p overexpression inhibits EndMT by inactivating both TGF-283 
β1 and the downstream target gene SMAD2. By contrast, TGF-β1 overexpression significantly 284 
abolishes the inhibitory effects of miR-142-3p (145). A negative regulation of glucose-induced 285 
EndMT in the heart is also played by miR-200b (146). In a recent study, the expression of specific 286 
fibrotic markers, such as vascular endothelial growth factor (VEGF) (147), zinc finger E-box–287 
binding homeobox (Zeb2) (148), and TGF-β1 (149) was prevented in diabetic mice overexpressing 288 
miR-200b (146). Moreover, miR-200b overexpression also induces the down-regulation of p300, 289 
a transcription coactivator known to contribute to cardiac fibrosis and hypertrophy via TGF-290 
β/SMAD (146, 150). Although the inhibitory role of the whole miR-200 family is well established, 291 
both in EMT (151, 152) and EndMT (146, 153), unexpectedly a recent study shown that miR-292 
200c-3p exerted the opposite effect, being able to promote EndMT and aortic graft remodeling 293 
both in vivo and in vitro (154). Finally, a further TGF-β/SMAD pathway-mediated regulatory 294 
mechanism involves miR-451 whose effects on EndMT are AMPK-dependent. Indeed, miR451 295 
knockdown in diabetic mouse hearts suppresses EndMT through the activation of AMPK, which 296 
in turn inhibits the TGF-β/SMAD pathway (155). As previously mentioned, in addition to TGF-297 
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β/SMAD, other pathways underlie the pathophysiological events leading to cardiac fibrosis. One 298 
of them is the Wnt signaling pathway, known to promote fibroblast activation and proliferation 299 
(156). On the other hand, the anti-fibrotic role of miRNA-221/222 family has been confirmed, as 300 
their down-regulation was associated with heart failure (157). The interplay between Wnt and 301 
miR‐222 in EndMT regulation has been recently suggested (158); specifically, miR‐222 is able to 302 
suppress the hyperglycemia‐induced EndMT and inhibit cardiac fibrosis by negatively regulating 303 
the Wnt/β‐catenin pathway in diabetic mice (158). Lastly, a further protective effect versus EndMT 304 
is exerted through the notch pathway and involves miR-18a-5p (159). The role of the notch 305 
pathway in heart development and control of the balance between fibrotic and regenerative repair 306 
in the adult heart has been widely confirmed (129). Moreover, Notch2 activation results essential 307 
for driving ECs differentiation (160, 161) in cardiovascular disease and for promoting EndMT 308 
independently or in association with TGF-β/SMAD3 signaling (162, 163). Notch2 is a target of 309 
miR-18a-5p which recently confirmed its antifibrotic role via the suppression of Notch2 and 310 
consequent inhibition of hyperglycemia-induced EndMT in human aortic valvular endothelial cells 311 
(HAVECs) (159). See figures and associated tables to overview of the signaling pathways 312 
involving both anti-fibrotic (Figure 1, Table 1) and pro-fibrotic (Figure 2, Table 2) miRNAs. 313 
 314 
Diabetic retinopathy 315 
Diabetic retinopathy (DR) is a common and severe microvascular complication of the eye that 316 
represents the leading cause of blindness in diabetes (164). The prevalence increases with disease 317 
progression and consequently with the exposure to the major risk factors, hyperglycemia and 318 
hypertension (165, 166). Generally, a tight blood glucose control is cornerstone to reduce the risk 319 
of DR progression (167). The condition is initially characterized by an asymptomatic stage, non-320 
proliferative diabetic retinopathy (NPDR), that involves increased vascular permeability and 321 
capillary occlusion. Retinal neovascularization, by contrast, predominates in a later stage, 322 
proliferative diabetic retinopathy (PDR) (168, 169), as consequence of hypoxia. However, as new 323 
vessels are relatively fragile, they tend to bleed into the macular region causing vision difficulties 324 
and, in the worst-case scenario, diabetic macular edema (DME), the main cause of blindness in 325 
DR (170). DME is described as a swelling of the macula due to fluid accumulation following 326 
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breakdown of the blood-retinal barrier (BRB). This event can occur both in the PDR and in the 327 
NPDR stage (171, 172). The BRB is composed of two distinct barriers: the outer BRB, consisting 328 
of retinal pigment epithelium and the inner BRB, composed of endothelial cells regulating the 329 
transport across retinal capillaries. Besides, the BRB is established by tight cellular junctions, both 330 
in the inner and outer barrier, as well as by the scarcity of endocytic vesicles within cells, which 331 
further ensure the integrity of the BRB (173, 174). In addition, pericytes, specialized mural cells 332 
with a central role in angiogenesis, regulate and stabilize this tight structure through the 333 
Angiopoietin-1/Tie-2, platelet-derived growth factor (PDGF) and TGF-β signaling pathways (175, 334 
176). BRB breakdown is a complex process involving different mechanisms; it can occur either in 335 
the inner BRB, the outer BRB, or both sites. The loss of integrity of the endothelial cell-cell 336 
junctions, the loss of pericytes and the thickening of the basement membrane are the major 337 
alterations observed in the inner BRB (172, 177). Several studies have shown that hyperglycemia 338 
represents the main risk factor contributing to the pathogenesis of diabetic retinopathy (172, 178, 339 
179). Furthermore, using a BRB model formed by retinal pericytes, astrocytes and endothelial 340 
cells, it has been recently reported that high glucose exposure elicits BRB breakdown, enhances 341 
BRB permeability and reduces the levels of junction proteins such as ZO-1 and VE-cadherin (180). 342 
Besides, elevated ROS as well as pro-inflammatory mediators (IL-1β, IL-6) and oxidative stress-343 
related enzymes (iNOS, Nox2) have also been shown to be increased (180). The major biochemical 344 
pathways involved in the BRB breakdown are the polyol pathway, the AGEs pathway, the PKC 345 
pathway and the hexosamine pathway. Oxidative stress and inflammation are responsible for the 346 
upregulation of growth factors and cytokines, such as vascular endothelial growth factor (VEGF), 347 
tumor necrosis factor (TNF), interleukins (ILs), and matrix metalloproteinases (MMPs), which 348 
contribute to the BRB breakdown and to the development of DME (172, 181-183). Studies have 349 
confirmed the role of the pro-angiogenic factor VEGF as main modulator of PDR and DME. VEGF 350 
is secreted by retinal pigmented epithelial cells, pericytes, and endothelial cells in response to 351 
hypoxia conditions caused by the obstruction and loss of retinal capillaries (171, 183). VEGF, in 352 
addition to promoting neovascularization in PDR, participates in the breakdown of the BRB via 353 
increasing permeability of retinal vessels (184). Indeed, high levels of VEGF increase the 354 
expression of the inflammatory intercellular adhesion molecule-1 (ICAM-1) which in turn 355 
facilitates the adhesion of leukocytes to the diabetic retinal vasculature, promoting capillary 356 




miRNAs regulation of DR-associated EndMT  359 
Hyperglycemia-induced increased production of ECM and thickening of the vascular basement 360 
membrane is the hallmark of diabetic retinopathy (186). As previously mentioned, hyperglycemia 361 
promotes fibrosis progression through the generation of ECs-derived myofibroblasts, EndMT. 362 
This process has been shown to play an important role also in the pathogenesis of DR (10). Similar 363 
to other diabetic complications, TGF-β is an important EndMT mediator, mainly through the 364 
activation of the SMAD signaling pathways (10, 187, 188). Moreover, the transcriptional activator 365 
p300, already known for increasing the expression of ECM proteins (189), and miR-200b have 366 
been described as key regulators of the TGF-β-mediated EndMT in diabetic mice (10). Although 367 
the specific mechanism played by miR-200b and p300 remains partially unknown, the anti-fibrotic 368 
activity of miR-200b, already described in other diabetic complications (146, 190), has also been 369 
confirmed in DR. Specifically, the EndMT observed in the retinas of wild-type diabetic mice was 370 
suppressed by the overexpression of miR-200b (10). As mentioned before, the outer BRB is 371 
composed of tight junctions of retina pigment epithelial cells (RPECs) which secrete various 372 
factors, nutrients and signaling molecules that influence the surrounding tissues (191, 192). 373 
Chronic hyperglycemia alters RPECs functions contributing to the fluid accumulation in DME and 374 
the development of DR (193). Under stress conditions RPECs cells can release large amounts of 375 
exosomes, nanoscale vesicles that mediate many intercellular activities such as cell-to-cell 376 
communication, immune regulation, inflammatory response, extracellular matrix turnover and 377 
neovascularization (194, 195). A recent study confirmed the importance of the crosstalk between 378 
ECs and RPECs cells in the progression of fibrosis in patients with DR (196). Specifically, it was 379 
observed that hyperglycemia increased the ability of RPECs to release miR-202-5p-enriched 380 
exosomes. On the other hand, hyperglycemia induced EndMT through the TGFβ signaling 381 
pathway activation in ECs. However, when ECs were treated with RPECs-derived exosomes, the 382 
hyperglycemia-induced TGFβ signaling pathway activation was significantly counteracted as well 383 
as the increased proliferation and migration (196). In addition, miR-202-5p, by targeting 384 
specifically TGFβR2, was responsible for the TGFβ signaling pathway inactivation and EndMT 385 
suppression (196). This study, in addition to providing additional evidence that hyperglycemia-386 
induced EndMT involves the activation of TGFβ signaling, also showed that the release of miR-387 
I  rev
202-5p-enriched exosomes from RPE cells leads to the suppression of EndMT. The RPE cells-388 
derived exosomes are therefore important mediators of the ECs-RPE cells c rosstalk in the 389 
development of DR (196). Additional miRNAs involved in EndMT regulation in DR include two 390 
members of the mi-RNA29 family, miR-29a and miR-29b, already described in fibrosis 391 
development associated with diabetic complications (79, 108, 197, 198). The anti-fibrotic activity 392 
of miR-29a/b has been recently confirmed also in DR where their overexpression suppressed the 393 
hyperglycemia-induced EndMT in human retinal microvascular endothelial cells (HRMECs) 394 
(199). The inhibitory effect of miR-29a/b was exerted through the down-regulation of the 395 
transmembrane protein Notch2, known to activate morphological and functional changes of ECs 396 
as well as promote EndMT (199, 200). See figures and associated tables to overview of the 397 
signaling pathways involving both anti-fibrotic (Figure 1, Table 1) and pro-fibrotic (Figure 2, 398 
Table 2) miRNAs. 399 
 400 
Atherosclerosis 401 
Atherosclerosis (AS) is characterized by plaque formation, secondary to the deposition of fats, 402 
cholesterol, and calcium, which lead to ischemia and its clinical manifestations, such as myocardial 403 
infarction and stroke (201). Although AS is classically associated with alterations of lipid 404 
metabolism and hypercholesterolemia (202), its pathogenesis is more complex and involves 405 
various factors. Endothelial dysfunction and inflammation are key steps in the sequence of events 406 
leading to AS (203, 204). The presence of mechanical stress, such as blood flow turbulence, can 407 
activate the endothelium, which responds by recruiting monocytes, adhesion molecules and pro-408 
inflammatory cytokines. Monocytes, facilitated by adhesion molecules and cytokines, infiltrate the 409 
intima and can differentiate in macrophages which actively participate in lipid uptake through 410 
phagocytosis (205). Diabetes and AS share several pathological mechanisms (206); indeed, the 411 
metabolic alterations that drive the development of diabetes are also involved in the pathogenesis 412 
of atherosclerosis (207, 208). In addition, both type 1 and type 2 diabetes can either induce 413 
atherosclerosis and accelerate its progression (207). In this context, a crucial role is played by the 414 
prolonged exposure to hyperglycemia and insulin resistance which are responsible for the 415 
increased atherosclerosis-related inflammation of the arterial wall (209, 210). In addition to 416 
triggering the onset and progression of diabetes, insulin resistance also promotes dyslipidemia, 417 
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hypertension and other metabolic abnormalities, important components of the pro-atherogenic 418 
milieu (209, 211). At the same time, an insufficient insulin signaling elicits an abnormal lipid 419 
metabolism and glucose transport and increase the production of glucose in the liver. Pancreatic β 420 
cells respond to hyperglycemia by increasing insulin secretion; however, the continued stimulation 421 
of β cells leads to their progressive functional failure and diabetes development (212, 213). 422 
Prolonged exposure to hyperglycemia increases oxidative stress (27, 214), the primary activator 423 
of signaling pathways driving AS and diabetes progression (215, 216). Overproduction of ROS 424 
increases the formation of advanced glycation end-products (AGEs), modifications of proteins or 425 
lipids that become non enzymatically glycated (209, 217). AGEs are involved in each step of 426 
atherosclerosis, being responsible for monocyte migration into the sub-endothelial space, release 427 
of cytokines by macrophages and stimulation of vasoconstriction (209). Moreover, the binding of 428 
AGEs to the receptor RAGE activates TGF-β, ERK, JNK, p38, NF-kB, PKC and the polyol 429 
pathways as well as maintaining the chronic pro-inflammatory state of the arterial wall (209, 218). 430 
 431 
miRNAs regulation of AS-associated EndMT  432 
As previously mentioned, endothelial dysfunction driven by oxidative stress plays a critical role 433 
in the development of AS. Persistent activation of ECs induces EndMT, which contributes to both 434 
the initiation and the progression of atherosclerosis (219, 220). Moreover, the extent of EndMT in 435 
the human plaque appears to be strongly correlated with the severity of the disease (12). A recent 436 
study showed the up-regulation of 17 miRNAs in atherosclerotic plaques; among them, miR-449a, 437 
already known for its role in lipid and cholesterol anabolism as well as inflammation (221), was 438 
significantly higher compared with normal arteries (222). The authors reported that miR-449a 439 
induces EndMT and promotes the development of AS by targeting the interaction between 440 
adiponectin receptor 2 (AdipoR2) and E-cadherin in lipid rafts (222). In this context, miR-449a 441 
has displayed a multilevel and complex regulatory mechanism by promoting proliferation and 442 
enhancing the migrating ability of ECs as well as their expression of atherosclerotic markers (222). 443 
The ability to induce EndMT was confirmed by the reduced E-cadherin expression concurrently 444 
with the increased expression of α-SMA and SMAD3 (222). miR-449a pro-atherosclerotic 445 
properties are exerted by inhibition AdipoR2 and E-cadherin migration into the lipid raft fractions 446 
of ECs and consequent suppression E-cadherin-AdipoR2 of interaction. Additionally, the authors 447 
In rev
iew
reported that blocking miR-449a protects diabetic mice from developing AS (222). Similarly to 448 
miR-449a, miR-374b was reported to be up-regulated both in atheroprone regions from mice and 449 
pigs and in TGF-β1-treated ECs (223). Additionally, the overexpression of miR-374b was 450 
associated with a reduction in endothelial markers (VE-Cadherin and eNOS), and a concomitant 451 
increase of mesenchymal markers (TAGLN and Calponin). Besides, miR-374b was able to induce 452 
EndMT through the silencing of the Mitogen-Activated Protein Kinase 7 (MAPK7) also known as 453 
ERK5 (223). MAPK7 is an antagonist of EndMT and its signaling activity is generally lost in 454 
vessel areas that are undergoing pathological remodeling (224, 225). Similarly, MAPK7 signaling 455 
activity was lost in the sites of vascular remodeling, providing an additional confirmation of the 456 
inhibitory action of miR-374b. By contrast, the recovery of MAPK7 signaling abrogated the 457 
pathological effect of miR-374b (223). miR-122, another miRNA recently reported as EndMT 458 
mediator in AS, has been shown to be up-regulated both in the aortic intima of diabetic mice and 459 
in the cellular EndMT model (226). The regulatory action of miR-122 is mediated by the neuronal 460 
PAS domain protein 3 (NPAS3). Indeed, inhibition of miR-122 prevented atherosclerosis and 461 
regulated NPAS3-mediated EndMT (226). miR-122 might therefore represent a druggable target 462 
in preventing EndMT-associated atherosclerosis. See figures and associated tables to overview of 463 
the signaling pathways involving both anti-fibrotic (Figure 1, Table 1) and pro-fibrotic (Figure 2, 464 
Table 2) miRNAs.   465 
 466 
Long non-coding RNAs regulation in diabetes-associated EndMT 467 
Besides miRNAs, small RNAs also include long non-coding RNAs (lncRNAs) and circular RNAs 468 
(circRNAs) which are emerging as key regulators implicated in a significant number of biological 469 
processes (227, 228). Unlike linear RNAs, circRNAs form a covalently closed continuous loop, 470 
without 5' or 3' ends (229). LncRNAs are instead linear RNAs, with a nucleotide length >200, that 471 
can affect gene transcription both at the epigenetic, transcriptional and post-transcriptional level 472 
(230, 231). Thus, LncRNAs can differently interact with mRNAs, proteins, and DNA elements; 473 
moreover, the binding of transcriptional factors to the lncRNA promoter's target sites can regulate 474 
their expression. (232). LncRNAs are also precursors of many types of miRNAs, although more 475 
frequently they overlap both physically and functionally with the latter. Moreover, lncRNAs 476 
compete with miRNAs for the binding to the same target genes and can trigger miRNAs 477 
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degradation (232, 233). Hence, lncRNAs are involved in a variety of human diseases where they 478 
appear differentially expressed or genetically perturbed (234, 235). In this context, most of the 479 
knowledge pertaining to lncRNAs is derived from cancer however there is increasing evidence of 480 
their involvement in other conditions, such as Alzheimer’s disease, diabetes, cardiac complications 481 
(46, 236, 237) and fibrosis (238-240). One important function of lncRNAs is their role as a 482 
molecular sponge to certain miRNAs, hindering their expression (241). This mechanism has been 483 
confirmed in diabetic kidney fibrosis, where the down-regulation of the anti-fibrotic miR-29 was 484 
associated with lncRNA H19 up-regulation, whereas its knockdown restored miR-29 activity and 485 
significantly inhibited TGF-β2-induced EndMT in diabetic mice (242). However, the role of H19 486 
in diabetes-associated EndMT remains unclear; indeed, H19 overexpression prevented glucose-487 
induced EndMT by reducing the TGF-β1 levels in DR (243). Further studies are required to clarify 488 
the role of H19 in regulating EndMT in diabetic conditions. Another lncRNA involved in DR is 489 
the maternally expressed gene 3 (MEG3) which showed an inhibitory effect on hyperglycemia-490 
induced EndMT. MEG3 resulted indeed able to suppress EndMT both in vivo and in vitro by 491 
inhibiting the PI3K/AKT/mTOR signaling pathway (244). On the other hand, MEG3 methylation 492 
mediated by DNA methyltransferase 1(DNMT1) attenuated MEG3 expression and consequently 493 
accelerated EndMT (244). This finding clarifies the role of MEG3 in EndMT and provide 494 
additional confirmation that increased levels of DNA methylation represent a potential risk factor 495 
for the development of DR (245). As previously reported, oxidized low density lipoproteins (ox-496 
LDL), being able to trigger plaque formation and EndMT, are key players in AS development 497 
(246). A recent study reported that miR-30c-5p and LINC00657, also known as noncoding RNA 498 
activated by DNA damage (NORAD), are both involved in ox-LDL-induced EndMT but with 499 
opposite effects (247). miR-30c-5p inhibited ox-LDL-induced EndMT via activation of the 500 
Wnt7b/β-catenin pathway whereas LINC00657, acting as sponge of miR-30c-5p, suppressed the 501 
EndMT inhibition (247). Indeed, the expression level of LINC00657 resulted elevated both in sera 502 
from AS patients and in ox-LDL-stimulated ECs (247). 503 
 504 
Potential ROS-EndMT-small RNAs interplay in diabetes-associated fibrotic conditions  505 
Oxidative stress is a key player in the diabetic complications' pathophysiology described in this 506 
review. Hyperglycemia is not only the main factor responsible for the increase in ROS but also 507 
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favors the increase of inflammatory mediators, which ultimately leads to vascular dysfunction 508 
(248). Both genetic and epigenetic factors can regulate the development and exacerbation of 509 
oxidative stress; in this context, different studies have highlighted the key role played by miRNAs 510 
(249). Indeed, hyperglycemia can alter miRNAs expression, which in turn contributes to the 511 
development of endothelium dysfunction and diabetic vascular disease (248). Besides, in diabetic 512 
complications the molecular mechanisms and signaling pathways triggered by oxidative stress 513 
appear similar to those involved in miRNAs regulation (249, 250). Finally, hyperglycemia-induced 514 
oxidative stress can affect the expression of specific miRNAs, which in turn can exacerbate 515 
oxidative stress, in addition to regulating the fibrotic process through the mechanisms summarized 516 
in this review (249, 250). On the other hand, oxidative stress is emerging as a key trigger of EndMT 517 
(25, 26). Therefore, although a direct oxidative stress-small RNAs-EndMT link has not been 518 
demonstrated in diabetes yet, a substantial body of evidence supports this interplay. For example, 519 
an indirect proof of a ROS-miR-21-EndMT link has been reported with kallistatin, an endogenous 520 
protein with beneficial effects on EndMT-associated fibrosis (251). Kallistatin treatment blocked 521 
TGF-β-induced EndMT, NADPH oxidase-dependent ROS formation and the expression of the 522 
pro-fibrotic miR-21, confirming the role of both miR-21 and ROS as major mediators of EndMT 523 
(251). Many studies indicated a direct link between mi-R21 and oxidative stress in diabetic 524 
subjects, where ROS generation has been suggested as a downstream effect of miR-21 525 
overexpression (252). The pro-oxidant effect of miR-21 is exerted through the suppression of 526 
genes which usually limit oxidative damage such as KRIT1 (Krev/Rap1 Interaction Trapped-1), 527 
Nuclear Factor erythroid Related Factor 2 (NRF2), and MnSOD2 (Manganese-dependent 528 
Superoxide Dismutase2). By contrast, inhibition of miR-21 decreases ROS levels (249, 253). A 529 
relationship between up-regulation of miR-21 and increased ROS levels has also been shown 530 
during the development of diabetic cardiac dysfunctions (254). The miR-200 family, the anti-531 
fibrotic activity of which has been described both in diabetic nephropathy and retinopathy, has 532 
also been shown to be associated with a decrease in oxidative stress in diabetes; specifically, the 533 
antioxidant effect of miR-200 is exerted by silencing the O-GlcNAc transferase, also known as 534 
OGT, whose enzymatic activity is associated with diabetic complications and endothelial 535 
inflammation (250). Another proof of the oxidative stress-small RNAs-EndMT interconnection 536 
comes from a study investigating the activity of miR-451 (255). The latter, previously described 537 
for its ability to induce EndMT in diabetic mouse heart (155), has been recently reported to be up-538 
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regulated in diabetic subjects with high oxidative stress. The association between miR-451 and 539 
oxidative stress has been further confirmed with the use of the antioxidant Vitamin C; indeed, 540 
Vitamin C administration in diabetic subjects decreased both the expression of miR-451 and ROS 541 
levels (255). Finally, an interplay being the basis of mitochondrial functions in kidney ECs 542 
involves the miR-let-7 family, (FGF)/FGFR1 signaling pathway and SIRT3 (256). The integrity 543 
of the FGFR1-miR-let-7 axis, on which depends the modulation of SIRT3, is crucial for 544 
maintaining the mitochondrial functionality (256). SIRT3, for its part, controls mitochondrial 545 
redox homeostasis by modulation of ROS levels (257, 258) mainly via activation of the antioxidant 546 
enzyme superoxide-dismutase 2 (259). On the contrary, the loss of the FGFR1-miR-let-7axis 547 
impairs SIRT3 and miR-29 levels with consequent disruption of mitochondrial integrity and 548 
activation of pro-mesenchymal signaling (Wnt signaling, BMP, Notch, TGF-β signaling) 549 
promoting EndMT (256) 550 
 551 
Conclusion and future directions 552 
This review has highlighted the key role of EndMT in the fibrotic process occurring in the 553 
development of the major diabetic complications. Environmental factors (high glucose, hypoxia, 554 
oxidative stress, pro-inflammatory cytokines) are important determinants of EndMT induction 555 
through the activation of specific signaling pathways, such as TGF-β, Notch, Wnt, and the 556 
modulation of the expression of microRNAs. The evidence reviewed in this article indicates that 557 
some microRNAs, e.g., miR-29, miR-200, and miR-Let7, have anti-fibrotic effects and inhibit 558 
EndMT whereas others, e.g., miR-21 and miR-122, possess pro-fibrotic properties and promote 559 
EndMT. The anti-fibrotic activity of some microRNAs appears univocal not only within diabetic 560 
complications but also in other pathological conditions. For instance, miR-29a/b and miR-200b 561 
have been shown to inhibit fibrosis in pulmonary fibrosis (260, 261), systemic sclerosis (106) as 562 
well as in DCM, DN and DR (10, 108, 146, 199). Similarly, miR-21 is generally up-regulated in 563 
different fibrotic diseases (96, 140) as well as in diabetic complications such as DN, DR and DCM 564 
(11, 144, 262). Moreover, since the expression levels of miR-21 in the plasma of diabetic patients 565 
were correlated with disease progression, miR-21 might be used as a marker of diabetes severity 566 
(263). On the other hand, the function of other microRNAs is only partially established in in vitro 567 
models or in specific pathological conditions. Further, for some miRNAs the evidence is still 568 
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controversial, such as the case of the lncRNA H19 which showed pro-fibrotic activity in DN (242) 569 
and an opposite effect in DR (243). Additionally, since the markers for EndMT used in individual 570 
studies are often different, a complete understanding of the regulatory mechanisms played by 571 
miRNAs, or an exact comparison between them, is currently challenging. In this regard, future 572 
directions in the study of diabetic complications should involve a) a thorough characterization of 573 
the mechanisms involved in the ROS-EndMT-small RNAs interplay and its relationship with the 574 
onset and severity of specific complications, b) the conduct of epidemiological studies 575 
investigating the association between specific miRNAs and lncRNAs and metabolic control, 576 
surrogate markers of organ damage, and morbidity and mortality in patients with diabetes, and c) 577 
the effects of specific pharmacological and non-pharmacological interventions targeting EndMT 578 
on the risk and progression of diabetic complications. Such studies might contribute to the 579 
identification of new diagnostic and therapeutic strategies to prevent or limit the structural and 580 
functional damage that leads to organ and system failure in diabetes. 581 
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Figures and Tables 601 
 602 
Figure 1. Anti-fibrotic miRNAs in diabetic complications.  603 
miR-142-3p and miR-200b inhibit EndMT by inactivating the TGF-β-SMAD pathway. The 604 
antifibrotic activity of miR-200b is played by down-regulating the TGF-β/SMAD pathway 605 
coactivator p300. miR-497 suppresses TGF-β-induced EndMT by ROCK1 and ROCK2 606 
inactivation. The overexpression of DPP-4 is associated with the suppression of the miR-29s 607 
family anti-fibrotic activity. However, both linagliptin and AcSDKP suppresses EndMT by 608 
restoring miR-29 and miR-let-7s activities. Furthermore, miR‐448‐3p inhibits EndMT via DPP‐4 609 
suppression. AcSDKP upregulates the antifibrotic miR-let-7 which suppresses TGFβR1 and TGFβ 610 
signaling. The block of TGFβ signaling results in up-regulation of miR-29 gene expression, which 611 
in turn causes FGFR1 phosphorylation. FGFR1 phosphorylation is critical for miR-let-7 612 
production. miR-29 can also target the profibrotic IFNY blocking its inhibitory action toward 613 
FGFR1. The miR-29s family inhibits high glucose-induced EndMT by down-regulating Notch2, 614 
which is also suppressed by miR-18a-5p. However, DPP-4 inhibitor and AcSDKP suppresses 615 
EndMT by restoring of miR-29 and miR-let-7s activities. Furthermore, miR‐448‐3p inhibit 616 
EndMT via DPP‐4 suppression. The miR-29s family inhibits high glucose-induced EndMT by the 617 
downregulation of Notch2 which is also suppressed by miR-18a-5p. High glucose-induced EndMT 618 
is also suppressed by miR-221/222 family, via the negative regulation of Wnt/β‐catenin, and by 619 
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miR-202-5p via inhibition of TGFβR2/TGFβ signaling pathway. Pro-fibrotic miRNAs are showed 620 
in dark, anti-fibrotic miRNAs in red. 621 
 622 
Anti-fibrotic miRNAs in diabetic complications 
miRNAs DN DR Other DCM Reference 







 TGFβ-p300 (10) 
(146) 
miR-202-5p  TGFβR2   (196) 











Notch2   (199) 
(44, 79, 111) 
miR-Let7 TGFβ signaling    (44, 79, 111) 
miR-448-3p   TGFβ 
signaling 
 (114) 
miR-18a-5p    Notch2 (159) 
 623 
Table 1. Anti-fibrotic miRNAs in diabetic complications. Table 1 summarizes the references 624 
describing the anti-fibrotic miRNAs in diabetic complication. DN: Diabetic Nephropathy; DR: 625 
Diabetic Retinopathy; DCM: Diabetic Cardiomyopathy. 626 
 627 




Figure 2. Pro-fibrotic miRNAs in diabetic complications.  630 
TGF-β increases miR-21 expression through Smad3 activation. miR‐21 expression is also directly 631 
increased by TGF-β and high glucose. miR-21 can in turn activates EndMT through releasing 632 
PTEN of Smad7 inhibition (red arrow). Indeed, both PTEN and SMAD7 are negative regulators 633 
of EndMT via the Akt and TGF-β1/Smad3 signaling respectively. SMAD7 can also suppress 634 
fibrosis by down-regulating the pro-fibrotics miR-21 and miR-192, and up-regulating the anti-635 
fibrotic miR-29b. miR451 triggers EndMT by blocking AMPK, an inhibitor of the TGF-β/SMAD 636 
pathway. miR-449a induces EndMT by inhibiting AdipoR2 and E-cadherin interaction in the lipid 637 
rafts. miR-374b plays its profibrotic activity by releasing MAPK7/ERK5-mediated EndMT 638 
inhibition. Finally, miR-122 activates EndMT via the neuronal PAS domain protein 3 (NPAS3). 639 







Pro-fibrotic miRNAs in diabetic complications 
miRNAs DN DR AS DCM Reference 
miR-21 TGFβ-SMAD    (11) 
miR-21 PTEN/Akt    (100) 
miR-21    NFkB/SMAD (144) 
miR-451    TGFβ-SMAD (155) 
miR-449   E-Cadherin/AdipoR2  (222) 
miR-374b   MAPK7/ERK  (223) 
miR-122   NPAS3  (226) 
 645 
Table 2. Pro-fibrotic miRNAs in diabetic complications. Table 2 summarizes the references 646 
describing the pro-fibrotic miRNAs in diabetic complications. DN: Diabetic Nephropathy; DR: 647 
Diabetic Retinopathy; DCM: Diabetic Cardiomyopathy; AS: Atherosclerosis. 648 
  649 In r v
iew
References. 650 
1. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and 651 
trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Scientific reports 652 
(2020) 10(1):1-11. 653 
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 654 
and 2030. Diabetes research and clinical practice (2010) 87(1):4-14. 655 
3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-656 
related complications. Physical therapy (2008) 88(11):1254-64. 657 
4. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. The Journal of clinical 658 
investigation (2005) 115(5):1111-9. 659 
5. Wynn TA. Cellular and molecular mechanisms of fibrosis. The Journal of Pathology: A 660 
Journal of the Pathological Society of Great Britain and Ireland (2008) 214(2):199-210. 661 
6. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and 662 
circulating and urinary markers. Vascular health and risk management (2008) 4(3):575. 663 
7. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. 664 
Frontiers in pharmacology (2014) 5:123. 665 
8. Micallef L, Vedrenne N, Billet F, Coulomb B, Darby IA, Desmoulière A, editors. The 666 
myofibroblast, multiple origins for major roles in normal and pathological tissue repair. 667 
Fibrogenesis & tissue repair; 2012: BioMed Central. 668 
9. Bochaton-Piallat M-L, Gabbiani G, Hinz B. The myofibroblast in wound healing and 669 
fibrosis: answered and unanswered questions. F1000Research (2016) 5. 670 
10. Cao Y, Feng B, Chen S, Chu Y, Chakrabarti S. Mechanisms of endothelial to mesenchymal 671 
transition in the retina in diabetes. Investigative ophthalmology & visual science (2014) 672 
55(11):7321-31. 673 
11. Srivastava SP, Koya D, Kanasaki K. MicroRNAs in kidney fibrosis and diabetic 674 
nephropathy: roles on EMT and EndMT. BioMed research international (2013) 2013. 675 
12. Souilhol C, Harmsen MC, Evans PC, Krenning G. Endothelial–mesenchymal transition in 676 
atherosclerosis. Cardiovascular research (2018) 114(4):565-77. 677 
13. Sandoo A, van Zanten JJV, Metsios GS, Carroll D, Kitas GD. The endothelium and its role 678 
in regulating vascular tone. The open cardiovascular medicine journal (2010) 4:302. 679 
14. Khaddaj Mallat R, Mathew John C, Kendrick DJ, Braun AP. The vascular endothelium: A 680 
regulator of arterial tone and interface for the immune system. Critical reviews in clinical 681 
laboratory sciences (2017) 54(7-8):458-70. 682 
15. Meza CA, La Favor JD, Kim D-H, Hickner RC. Endothelial dysfunction: is there a 683 
hyperglycemia-induced imbalance of NOX and NOS? International journal of molecular sciences 684 
(2019) 20(15):3775. 685 
16. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and 686 
diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and tissue research 687 
(2009) 335(1):165-89. 688 
I  ev
iew
17. Yu C-H, Gong M, Liu W-J, Cui N-X, Wang Y, Du X, et al. High glucose induced 689 
endothelial to mesenchymal transition in human umbilical vein endothelial cell. Experimental and 690 
molecular pathology (2017) 102(3):377-83. 691 
18. Giordo R, Nasrallah GK, Posadino AM, Galimi F, Capobianco G, Eid AH, et al. 692 
Resveratrol-Elicited PKC Inhibition Counteracts NOX-Mediated Endothelial to Mesenchymal 693 
Transition in Human Retinal Endothelial Cells Exposed to High Glucose. Antioxidants (2021) 694 
10(2):224. 695 
19. Cho JG, Lee A, Chang W, Lee M-S, Kim J. Endothelial to mesenchymal transition 696 
represents a key link in the interaction between inflammation and endothelial dysfunction. 697 
Frontiers in immunology (2018) 9:294. 698 
20. Man S, Duffhues GS, Ten Dijke P, Baker D. The therapeutic potential of targeting the 699 
endothelial-to-mesenchymal transition. Angiogenesis (2019) 22(1):3-13. 700 
21. Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. Nature 701 
communications (2017) 8(1):1-11. 702 
22. Hong L, Du X, Li W, Mao Y, Sun L, Li X. EndMT: a promising and controversial field. 703 
European journal of cell biology (2018) 97(7):493-500. 704 
23. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman K-705 
R, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is 706 
associated with plaque instability. Nature communications (2016) 7(1):1-16. 707 
24. Phan THG, Paliogiannis P, Nasrallah GK, Giordo R, Eid AH, Fois AG, et al. Emerging 708 
cellular and molecular determinants of idiopathic pulmonary fibrosis. Cellular and Molecular Life 709 
Sciences (2020):1-27. 710 
25. Thuan DTB, Zayed H, Eid AH, Abou-Saleh H, Nasrallah GK, Mangoni AA, et al. A 711 
potential link between oxidative stress and endothelial-to-mesenchymal transition in systemic 712 
sclerosis. Frontiers in immunology (2018) 9:1985. 713 
26. Montorfano I, Becerra A, Cerro R, Echeverría C, Sáez E, Morales MG, et al. Oxidative 714 
stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β 1 and TGF-β 715 
2-dependent pathway. Laboratory investigation (2014) 94(10):1068-82. 716 
27. Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, 717 
reactive oxygen species (ROS) and diabetic complications. Cell death & disease (2018) 9(2):1-9. 718 
28. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, et al. High 719 
glucose‐induced oxidative stress and mitochondrial dysfunction in neurons. The FASEB Journal 720 
(2002) 16(13):1738-48. 721 
29. Li Q, Lin Y, Wang S, Zhang L, Guo L. GLP-1 inhibits high-glucose-induced oxidative 722 
injury of vascular endothelial cells. Scientific reports (2017) 7(1):1-9. 723 
30. Peng C, Ma J, Gao X, Tian P, Li W, Zhang L. High glucose induced oxidative stress and 724 
apoptosis in cardiac microvascular endothelial cells are regulated by FoxO3a. PLoS One (2013) 725 
8(11):e79739. 726 
31. Piera-Velazquez S, Jimenez SA. Endothelial to mesenchymal transition: role in physiology 727 
and in the pathogenesis of human diseases. Physiological reviews (2019) 99(2):1281-324. 728 
In rev
ew
32. Lin Q, Zhao J, Zheng C, Chun J. Roles of notch signaling pathway and endothelial-729 
mesenchymal transition in vascular endothelial dysfunction and atherosclerosis. Eur Rev Med 730 
Pharmacol Sci (2018) 22:6485-91. 731 
33. Ursoli Ferreira F, Eduardo Botelho Souza L, Hassibe Thomé C, Tomazini Pinto M, 732 
Origassa C, Salustiano S, et al. Endothelial cells tissue-specific origins affects their responsiveness 733 
to TGF-β2 during endothelial-to-mesenchymal transition. International journal of molecular 734 
sciences (2019) 20(3):458. 735 
34. Kim J-D, Lee A, Choi J, Park Y, Kang H, Chang W, et al. Epigenetic modulation as a 736 
therapeutic approach for pulmonary arterial hypertension. Experimental & molecular medicine 737 
(2015) 47(7):e175-e. 738 
35. Michlewski G, Cáceres JF. Post-transcriptional control of miRNA biogenesis. Rna (2019) 739 
25(1):1-16. 740 
36. Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. 741 
Trends in cell biology (2015) 25(3):137-47. 742 
37. Kehl T, Backes C, Kern F, Fehlmann T, Ludwig N, Meese E, et al. About miRNAs, miRNA 743 
seeds, target genes and target pathways. Oncotarget (2017) 8(63):107167. 744 
38. Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview 745 
of nuclear functions. International journal of molecular sciences (2016) 17(10):1712. 746 
39. Fan B, Chopp M, Zhang ZG, Liu XS. Emerging roles of microRNAs as biomarkers and 747 
therapeutic targets for diabetic neuropathy. Frontiers in Neurology (2020) 11. 748 
40. Regazzi R. MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its 749 
complications. Expert opinion on therapeutic targets (2018) 22(2):153-60. 750 
41. Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic 751 
targets in diabetic kidney disease: an update. FASEB BioAdvances (2019) 1(6):375-88. 752 
42. Ghosh AK, Nagpal V, Covington JW, Michaels MA, Vaughan DE. Molecular basis of 753 
cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs 754 
during EndMT. Cellular signalling (2012) 24(5):1031-6. 755 
43. Kim J. MicroRNAs as critical regulators of the endothelial to mesenchymal transition in 756 
vascular biology. BMB reports (2018) 51(2):65. 757 
44. Srivastava SP, Hedayat AF, Kanasaki K, Goodwin JE. Microrna crosstalk influences 758 
epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal 759 
transitions in the kidney. Frontiers in pharmacology (2019) 10:904. 760 
45. Feng S-D, Yang J-H, Yao CH, Yang S-S, Zhu Z-M, Wu D, et al. Potential regulatory 761 
mechanisms of lncRNA in diabetes and its complications. Biochemistry and Cell Biology (2017) 762 
95(3):361-7. 763 
46. Leung A, Natarajan R. Long noncoding RNAs in diabetes and diabetic complications. 764 
Antioxidants & redox signaling (2018) 29(11):1064-73. 765 
47. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative 766 
annotation of human large intergenic noncoding RNAs reveals global properties and specific 767 
subclasses. Genes & development (2011) 25(18):1915-27. 768 
In rev
i w
48. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. 769 
Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care (2005) 28(1):164-76. 770 
49. Rheinberger M, Böger C. Diabetic nephropathy: new insights into diagnosis, prevention 771 
and treatment. Deutsche medizinische Wochenschrift (1946) (2014) 139(14):704-6. 772 
50. Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C, Rayego-Mateos S. Special issue “diabetic 773 
nephropathy: Diagnosis, prevention and treatment”. Multidisciplinary Digital Publishing Institute 774 
(2020). 775 
51. Lim AK. Diabetic nephropathy–complications and treatment. International journal of 776 
nephrology and renovascular disease (2014) 7:361. 777 
52. Lewis G, Maxwell AP. Risk factor control is key in diabetic nephropathy. Practitioner 778 
(2014) 258(1768):13-7. 779 
53. Mogensen C, Christensen C, Vittinghus E. The stages in diabetic renal disease: with 780 
emphasis on the stage of incipient diabetic nephropathy. Diabetes (1983) 32(Supplement 2):64-781 
78. 782 
54. Calle P, Hotter G. Macrophage phenotype and fibrosis in diabetic nephropathy. 783 
International journal of molecular sciences (2020) 21(8):2806. 784 
55. Brosius FC. New insights into the mechanisms of fibrosis and sclerosis in diabetic 785 
nephropathy. Reviews in Endocrine and Metabolic Disorders (2008) 9(4):245-54. 786 
56. Aghadavoud E, Nasri H, Amiri M. Molecular signaling pathways of diabetic kidney 787 
disease; new concepts. Journal of Preventive Epidemiology (2017) 2(2):e09-e. 788 
57. Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. 789 
American Journal of Kidney Diseases (2014) 63(2):S63-S83. 790 
58. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining 791 
the links. International journal of physiology, pathophysiology and pharmacology (2019) 792 
11(3):45. 793 
59. Kashihara N, Haruna Y, K Kondeti V, S Kanwar Y. Oxidative stress in diabetic 794 
nephropathy. Current medicinal chemistry (2010) 17(34):4256-69. 795 
60. Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its 796 
inhibition as new therapeutic targets. Journal of diabetes research (2013) 2013. 797 
61. Koya D, King GL. Protein kinase C activation and the development of diabetic 798 
complications. Diabetes (1998) 47(6):859-66. 799 
62. Evcimen ND, King GL. The role of protein kinase C activation and the vascular 800 
complications of diabetes. Pharmacological research (2007) 55(6):498-510. 801 
63. Chen F, Yu Y, Haigh S, Johnson J, Lucas R, Stepp DW, et al. Regulation of NADPH 802 
oxidase 5 by protein kinase C isoforms. PloS one (2014) 9(2):e88405. 803 
64. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radical 804 
Biology and Medicine (1994) 16(3):383-91. 805 
65. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: 806 
regulation and biological consequences. Antioxidants & redox signaling (2008) 10(2):179-206. 807 
In r v
w
66. Hummel SG, Fischer AJ, Martin SM, Schafer FQ, Buettner GR. Nitric oxide as a cellular 808 
antioxidant: a little goes a long way. Free radical biology and medicine (2006) 40(3):501-6. 809 
67. Zhao Y, Zhang J, Li H, Li Y, Ren J, Luo M, et al. An NADPH sensor protein (HSCARG) 810 
down-regulates nitric oxide synthesis by association with argininosuccinate synthetase and is 811 
essential for epithelial cell viability. Journal of Biological Chemistry (2008) 283(16):11004-13. 812 
68. Schiffrin EL. Oxidative stress, nitric oxide synthase, and superoxide dismutase: a matter 813 
of imbalance underlies endothelial dysfunction in the human coronary circulation. Am Heart 814 
Assoc (2008). 815 
69. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: 816 
sparking the development of diabetic vascular injury. Circulation (2006) 114(6):597-605. 817 
70. Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular 818 
complications. Diabetes & metabolism journal (2018) 42(3):188. 819 
71. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The 820 
ubiquitous system for homeostasis and pathologies. Biomedicine & Pharmacotherapy (2017) 821 
94:317-25. 822 
72. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, 823 
immunology and aging. EMBO molecular medicine (2010) 2(7):247-57. 824 
73. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin–angiotensin–aldosterone system, 825 
glucose metabolism and diabetes. Trends in Endocrinology & Metabolism (2005) 16(3):120-6. 826 
74. Williams VR, Scholey JW. Angiotensin-converting enzyme 2 and renal disease. Current 827 
opinion in nephrology and hypertension (2018) 27(1):35-41. 828 
75. Batlle D, Soler MJ, Ye M. ACE2 and diabetes: ACE of ACEs? Diabetes (2010) 829 
59(12):2994-6. 830 
76. Pathak JV, Dass EE. A retrospective study of the effects of angiotensin receptor blockers 831 
and angiotensin converting enzyme inhibitors in diabetic nephropathy. Indian journal of 832 
pharmacology (2015) 47(2):148. 833 
77. Anand S, Tamura MK. Combining angiotensin receptor blockers with ACE inhibitors in 834 
elderly patients. American journal of kidney diseases: the official journal of the National Kidney 835 
Foundation (2012) 59(1):11. 836 
78. Nitta K, Shi S, Nagai T, Kanasaki M, Kitada M, Srivastava SP, et al. Oral administration 837 
of N-acetyl-seryl-aspartyl-lysyl-proline ameliorates kidney disease in both type 1 and type 2 838 
diabetic mice via a therapeutic regimen. BioMed research international (2016) 2016. 839 
79. Srivastava SP, Goodwin JE, Kanasaki K, Koya D. Inhibition of angiotensin-converting 840 
enzyme ameliorates renal fibrosis by mitigating dpp-4 level and restoring antifibrotic micrornas. 841 
Genes (2020) 11(2):211. 842 
80. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of 843 




81. Srivastava SP, Li J, Kitada M, Fujita H, Yamada Y, Goodwin JE, et al. SIRT3 deficiency 846 
leads to induction of abnormal glycolysis in diabetic kidney with fibrosis. Cell death & disease 847 
(2018) 9(10):1-14. 848 
82. Locatelli M, Zoja C, Zanchi C, Corna D, Villa S, Bolognini S, et al. Manipulating Sirtuin 849 
3 pathway ameliorates renal damage in experimental diabetes. Scientific reports (2020) 10(1):1-850 
12. 851 
83. Yue B. Biology of the extracellular matrix: an overview. Journal of glaucoma (2014):S20. 852 
84. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. Journal of cell 853 
science (2010) 123(24):4195-200. 854 
85. Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. 855 
The Journal of clinical investigation (2018) 128(1):45-53. 856 
86. Zent J, Guo L-W. Signaling mechanisms of myofibroblastic activation: outside-in and 857 
inside-out. Cellular Physiology and Biochemistry (2018) 49(3):848-68. 858 
87. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney 859 
fibrosis emerge via endothelial-to-mesenchymal transition. Journal of the American Society of 860 
Nephrology (2008) 19(12):2282-7. 861 
88. Curci C, Castellano G, Stasi A, Divella C, Loverre A, Gigante M, et al. Endothelial-to-862 
mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by 863 
complement anaphylatoxins and Akt pathway. Nephrology Dialysis Transplantation (2014) 864 
29(4):799-808. 865 
89. Sun YBY, Qu X, Caruana G, Li J. The origin of renal fibroblasts/myofibroblasts and the 866 
signals that trigger fibrosis. Differentiation (2016) 92(3):102-7. 867 
90. Li J, Liu H, Srivastava SP, Hu Q, Gao R, Li S, et al. Endothelial FGFR1 (fibroblast growth 868 
factor receptor 1) deficiency contributes differential fibrogenic effects in kidney and heart of 869 
diabetic mice. Hypertension (2020) 76(6):1935-44. 870 
91. Srivastava SP, Goodwin JE, Kanasaki K, Koya D. Metabolic reprogramming by N‐acetyl‐871 
seryl‐aspartyl‐lysyl‐proline protects against diabetic kidney disease. British journal of 872 
pharmacology (2020) 177(16):3691-711. 873 
92. Glover EK, Jordan N, Sheerin NS, Ali S. Regulation of endothelial-to-mesenchymal 874 
transition by microRNAs in chronic allograft dysfunction. Transplantation (2019) 103(4):e64. 875 
93. Hulshoff MS, del Monte-Nieto G, Kovacic J, Krenning G. Non-coding RNA in 876 
endothelial-to-mesenchymal transition. Cardiovascular research (2019) 115(12):1716-31. 877 
94. Wang Z, Han Z, Tao J, Wang J, Liu X, Zhou W, et al. Role of endothelial‐to‐mesenchymal 878 
transition induced by TGF‐β1 in transplant kidney interstitial fibrosis. Journal of cellular and 879 
molecular medicine (2017) 21(10):2359-69. 880 
95. Wang Z, Han Z, Tao J, Wang J, Liu X, Zhou W, et al. Transforming growth factor-β1 881 
induces endothelial-to-mesenchymal transition via Akt signaling pathway in renal transplant 882 
recipients with chronic allograft dysfunction. Medical Science Monitor (2016) 21:775-83. 883 
96. Huang Y, He Y, Li J. MicroRNA-21: a central regulator of fibrotic diseases via various 884 
targets. Current pharmaceutical design (2015) 21(17):2236-42. 885 
In rev
i w
97. Zhong X, Chung AC, Chen H-Y, Meng X-M, Lan HY. Smad3-mediated upregulation of 886 
miR-21 promotes renal fibrosis. Journal of the American Society of Nephrology (2011) 887 
22(9):1668-81. 888 
98. Loboda A, Sobczak M, Jozkowicz A, Dulak J. TGF-β1/Smads and miR-21 in renal fibrosis 889 
and inflammation. Mediators of inflammation (2016) 2016. 890 
99. Chung AC, Dong Y, Yang W, Zhong X, Li R, Lan HY. Smad7 suppresses renal fibrosis 891 
via altering expression of TGF-β/Smad3-regulated microRNAs. Molecular Therapy (2013) 892 
21(2):388-98. 893 
100. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park D-H, Thum T. Transforming 894 
growth factor-β–induced endothelial-to-mesenchymal transition is partly mediated by microRNA-895 
21. Arteriosclerosis, thrombosis, and vascular biology (2012) 32(2):361-9. 896 
101. Medici D, Potenta S, Kalluri R. Transforming growth factor-β2 promotes Snail-mediated 897 
endothelial–mesenchymal transition through convergence of Smad-dependent and Smad-898 
independent signalling. Biochemical Journal (2011) 437(3):515-20. 899 
102. Meadows KN, Iyer S, Stevens MV, Wang D, Shechter S, Perruzzi C, et al. Akt promotes 900 
endocardial-mesenchyme transition. Journal of angiogenesis research (2009) 1(1):1-9. 901 
103. Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the 902 
treatment of type 2 diabetes. Frontiers in endocrinology (2019) 10:80. 903 
104. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, et al. Interactions of DPP-4 904 
and integrin β1 influences endothelial-to-mesenchymal transition. Kidney international (2015) 905 
88(3):479-89. 906 
105. Kanasaki K. The pathological significance of dipeptidyl peptidase-4 in endothelial cell 907 
homeostasis and kidney fibrosis. Diabetology international (2016) 7(3):212-20. 908 
106. Harmanci D, Erkan EP, Kocak A, Akdogan GG. Role of the microRNA-29 family in 909 
fibrotic skin diseases. Biomedical reports (2017) 6(6):599-604. 910 
107. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, 911 
and relevance to renal and cardiovascular injury. Physiological genomics (2012) 44(4):237-44. 912 
108. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated 913 
DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting 914 
endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes (2014) 63(6):2120-31. 915 
109. Nagai T, Kanasaki M, Srivastava SP, Nakamura Y, Ishigaki Y, Kitada M, et al. N-acetyl-916 
seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-917 
mesenchymal transition. BioMed research international (2014) 2014. 918 
110. Hrenak J, Paulis L, Simko F. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): potential 919 
target molecule in research of heart, kidney and brain. Current pharmaceutical design (2015) 920 
21(35):5135-43. 921 
111. Srivastava SP, Shi S, Kanasaki M, Nagai T, Kitada M, He J, et al. Effect of antifibrotic 922 
microRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related 923 
kidney fibrosis. Scientific reports (2016) 6(1):1-12. 924 
In r v
iew
112. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, et al. The microRNA miR-29 controls innate 925 
and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nature 926 
immunology (2011) 12(9):861-9. 927 
113. Chen P-Y, Qin L, Barnes C, Charisse K, Yi T, Zhang X, et al. FGF regulates TGF-β 928 
signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell 929 
reports (2012) 2(6):1684-96. 930 
114. Guan GY, Wei N, Song T, Zhao C, Sun Y, Pan RX, et al. miR‐448‐3p alleviates diabetic 931 
vascular dysfunction by inhibiting endothelial–mesenchymal transition through DPP‐4 932 
dysregulation. Journal of Cellular Physiology (2020) 235(12):10024-36. 933 
115. Liu F, Zhang S, Xu R, Gao S, Yin J. Melatonin attenuates endothelial-to-mesenchymal 934 
transition of glomerular endothelial cells via regulating miR-497/ROCK in diabetic nephropathy. 935 
Kidney and Blood Pressure Research (2018) 43(5):1425-36. 936 
116. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling 937 
ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes (2008) 938 
57(3):714-23. 939 
117. Matoba K, Takeda Y, Nagai Y, Kanazawa Y, Kawanami D, Yokota T, et al. ROCK 940 
Inhibition May Stop Diabetic Kidney Disease. JMA journal (2020) 3(3):154-63. 941 
118. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Reviews in Endocrine 942 
and Metabolic Disorders (2010) 11(1):31-9. 943 
119. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms 944 
contributing to this clinical entity. Circulation research (2018) 122(4):624-38. 945 
120. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic 946 
cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nature 947 
Reviews Cardiology (2020) 17(9):585-607. 948 
121. Brunvand L, Heier M, Brunborg C, Hanssen KF, Fugelseth D, Stensaeth KH, et al. 949 
Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart 950 
function. BMC cardiovascular disorders (2017) 17(1):1-6. 951 
122. Tan KC, Chow W-S, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products 952 
and endothelial dysfunction in type 2 diabetes. Diabetes care (2002) 25(6):1055-9. 953 
123. Yan D, Luo X, Li Y, Liu W, Deng J, Zheng N, et al. Effects of advanced glycation end 954 
products on calcium handling in cardiomyocytes. Cardiology (2014) 129(2):75-83. 955 
124. Dikalov SI, Nazarewicz RR. Angiotensin II-induced production of mitochondrial reactive 956 
oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxidants & 957 
redox signaling (2013) 19(10):1085-94. 958 
125. Siasos G, Tsigkou V, Kosmopoulos M, Theodosiadis D, Simantiris S, Tagkou NM, et al. 959 
Mitochondria and cardiovascular diseases—from pathophysiology to treatment. Annals of 960 
translational medicine (2018) 6(12). 961 
126. Gollmer J, Zirlik A, Bugger H. Established and emerging mechanisms of diabetic 962 
cardiomyopathy. Journal of Lipid and Atherosclerosis (2019) 8(1):26. 963 
In rev
iew
127. Ma Z-G, Yuan Y-P, Wu H-M, Zhang X, Tang Q-Z. Cardiac fibrosis: new insights into the 964 
pathogenesis. International journal of biological sciences (2018) 14(12):1645. 965 
128. Hortells L, Johansen AKZ, Yutzey KE. Cardiac fibroblasts and the extracellular matrix in 966 
regenerative and nonregenerative hearts. Journal of cardiovascular development and disease 967 
(2019) 6(3):29. 968 
129. Nemir M, Metrich M, Plaisance I, Lepore M, Cruchet S, Berthonneche C, et al. The Notch 969 
pathway controls fibrotic and regenerative repair in the adult heart. European heart journal (2014) 970 
35(32):2174-85. 971 
130. Yousefi F, Shabaninejad Z, Vakili S, Derakhshan M, Movahedpour A, Dabiri H, et al. 972 
TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus. Cell 973 
Communication and Signaling (2020) 18(1):1-16. 974 
131. Hu Q, Li J, Nitta K, Kitada M, Nagai T, Kanasaki K, et al. FGFR1 is essential for N-acetyl-975 
seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-976 
7b-5p. Biochemical and biophysical research communications (2018) 495(3):2214-20. 977 
132. Kovacic JC, Mercader N, Torres M, Boehm M, Fuster V. Epithelial-to-mesenchymal and 978 
endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation 979 
(2012) 125(14):1795-808. 980 
133. Guo R, Nair S. Role of microRNA in diabetic cardiomyopathy: from mechanism to 981 
intervention. Biochimica et biophysica acta (BBA)-molecular basis of disease (2017) 982 
1863(8):2070-7. 983 
134. Nandi SS, Mishra PK. Targeting miRNA for therapy of juvenile and adult diabetic 984 
cardiomyopathy.  Exosomes, Stem Cells and MicroRNA. Springer (2018). p. 47-59. 985 
135. Sharma V, Dogra N, Saikia UN, Khullar M. Transcriptional regulation of endothelial-to-986 
mesenchymal transition in cardiac fibrosis: role of myocardin-related transcription factor A and 987 
activating transcription factor 3. Canadian journal of physiology and pharmacology (2017) 988 
95(10):1263-70. 989 
136. Widyantoro B. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic 990 
heart through endothelial-to-mesenchymal transition: 神戸大学 (2010). 991 
137. Sánchez‐Duffhues G, García de Vinuesa A, Ten Dijke P. Endothelial‐to‐mesenchymal 992 
transition in cardiovascular diseases: developmental signaling pathways gone awry. 993 
Developmental Dynamics (2018) 247(3):492-508. 994 
138. Wang J, Liew OW, Richards AM, Chen Y-T. Overview of microRNAs in cardiac 995 
hypertrophy, fibrosis, and apoptosis. International journal of molecular sciences (2016) 17(5):749. 996 
139. Wang H, Cai J. The role of microRNAs in heart failure. Biochimica et Biophysica Acta 997 
(BBA)-Molecular Basis of Disease (2017) 1863(8):2019-30. 998 
140. Liu RH, Ning B, Ma XE, Gong WM, Jia TH. Regulatory roles of microRNA-21 in fibrosis 999 
through interaction with diverse pathways. Molecular medicine reports (2016) 13(3):2359-66. 1000 
141. Adam O, Löhfelm B, Thum T, Gupta SK, Puhl S-L, Schäfers H-J, et al. Role of miR-21 in 1001 
the pathogenesis of atrial fibrosis. Basic research in cardiology (2012) 107(5):278. 1002 
In rev
iew
142. Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y, et al. Mir-21 promotes cardiac fibrosis after 1003 
myocardial infarction via targeting Smad7. Cellular Physiology and Biochemistry (2017) 1004 
42(6):2207-19. 1005 
143. Dai B, Li H, Fan J, Zhao Y, Yin Z, Nie X, et al. MiR-21 protected against diabetic 1006 
cardiomyopathy induced diastolic dysfunction by targeting gelsolin. Cardiovascular diabetology 1007 
(2018) 17(1):1-17. 1008 
144. Li Q, Yao Y, Shi S, Zhou M, Zhou Y, Wang M, et al. Inhibition of miR‐21 alleviated 1009 
cardiac perivascular fibrosis via repressing EndMT in T1DM. Journal of cellular and molecular 1010 
medicine (2020) 24(1):910-20. 1011 
145. Zhu G-H, Li R, Zeng Y, Zhou T, Xiong F, Zhu M. MicroRNA-142-3p inhibits high-1012 
glucose-induced endothelial-to-mesenchymal transition through targeting TGF-β1/Smad pathway 1013 
in primary human aortic endothelial cells. International journal of clinical and experimental 1014 
pathology (2018) 11(3):1208. 1015 
146. Feng B, Cao Y, Chen S, Chu X, Chu Y, Chakrabarti S. miR-200b mediates endothelial-to-1016 
mesenchymal transition in diabetic cardiomyopathy. Diabetes (2016) 65(3):768-79. 1017 
147. Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al. Vascular endothelial 1018 
growth factor promotes fibrosis resolution and repair in mice. Gastroenterology (2014) 1019 
146(5):1339-50. e1. 1020 
148. Jahan F, Landry NM, Rattan SG, Dixon I, Wigle JT. The functional role of zinc finger E 1021 
box-binding homeobox 2 (Zeb2) in promoting cardiac fibroblast activation. International journal 1022 
of molecular sciences (2018) 19(10):3207. 1023 
149. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth 1024 
factors (2011) 29(5):196-202. 1025 
150. Bugyei-Twum A, Advani A, Advani SL, Zhang Y, Thai K, Kelly DJ, et al. High glucose 1026 
induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis 1027 
and hypertrophy. Cardiovascular diabetology (2014) 13(1):1-12. 1028 
151. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-1029 
mesenchymal transition and cancer metastasis. RNA biology (2008) 5(3):115-9. 1030 
152. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal 1031 
transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors 1032 
ZEB1 and ZEB2. Journal of Biological Chemistry (2008) 283(22):14910-4. 1033 
153. Zhang H, Hu J, Liu L. MiR-200a modulates TGF-β1-induced endothelial-to-mesenchymal 1034 
shift via suppression of GRB2 in HAECs. Biomedicine & Pharmacotherapy (2017) 95:215-22. 1035 
154. Chen D, Zhang C, Chen J, Yang M, Afzal TA, An W, et al. miRNA‐200c‐3p promotes 1036 
endothelial to mesenchymal transition and neointimal hyperplasia in artery bypass grafts. The 1037 
Journal of pathology (2021) 253(2):209-24. 1038 
155. Liang C, Gao L, Liu Y, Liu Y, Yao R, Li Y, et al. MiR-451 antagonist protects against 1039 
cardiac fibrosis in streptozotocin-induced diabetic mouse heart. Life sciences (2019) 224:12-22. 1040 
156. Tao H, Yang J-J, Shi K-H, Li J. Wnt signaling pathway in cardiac fibrosis: new insights 1041 
and directions. Metabolism (2016) 65(2):30-40. 1042 
I rev
iew
157. Verjans R, Peters T, Beaumont FJ, van Leeuwen R, van Herwaarden T, Verhesen W, et al. 1043 
MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload–induced heart 1044 
failure. Hypertension (2018) 71(2):280-8. 1045 
158. Wang Z, Wang Z, Gao L, Xiao L, Yao R, Du B, et al. miR‐222 inhibits cardiac fibrosis in 1046 
diabetic mice heart via regulating Wnt/β‐catenin‐mediated endothelium to mesenchymal 1047 
transition. Journal of cellular physiology (2020) 235(3):2149-60. 1048 
159. Geng H, Guan J. MiR-18a-5p inhibits endothelial–mesenchymal transition and cardiac 1049 
fibrosis through the Notch2 pathway. Biochemical and biophysical research communications 1050 
(2017) 491(2):329-36. 1051 
160. Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R, et al. Notch activation 1052 
results in phenotypic and functional changes consistent with endothelial-to-mesenchymal 1053 
transformation. Circulation research (2004) 94(7):910-7. 1054 
161. Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, et al. Endothelial 1055 
to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. Journal of the 1056 
American College of Cardiology (2019) 73(2):190-209. 1057 
162. Fu Y, Chang A, Chang L, Niessen K, Eapen S, Setiadi A, et al. Differential regulation of 1058 
transforming growth factor β signaling pathways by Notch in human endothelial cells. Journal of 1059 
Biological Chemistry (2009) 284(29):19452-62. 1060 
163. Chang AC, Fu Y, Garside VC, Niessen K, Chang L, Fuller M, et al. Notch initiates the 1061 
endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of 1062 
soluble guanylyl cyclase. Developmental cell (2011) 21(2):288-300. 1063 
164. Sabanayagam C, Yip W, Ting DS, Tan G, Wong TY. Ten emerging trends in the 1064 
epidemiology of diabetic retinopathy. Ophthalmic epidemiology (2016) 23(4):209-22. 1065 
165. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular 1066 
edema and related vision loss. Eye and vision (2015) 2(1):1-25. 1067 
166. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular 1068 
edema. Current diabetes reports (2012) 12(4):346-54. 1069 
167. Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Progress 1070 
in retinal and eye research (2008) 27(2):161-76. 1071 
168. Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. 1072 
Vision research (2017) 139:7-14. 1073 
169. Kusuhara S, Fukushima Y, Ogura S, Inoue N, Uemura A. Pathophysiology of diabetic 1074 
retinopathy: the old and the new. Diabetes & metabolism journal (2018) 42(5):364. 1075 
170. Wang W, Lo AC. Diabetic retinopathy: pathophysiology and treatments. International 1076 
journal of molecular sciences (2018) 19(6):1816. 1077 
171. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, 1078 
Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. Journal of 1079 
diabetes research (2016) 2016. 1080 
172. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel 1081 
therapeutic targets. Ophthalmology (2015) 122(7):1375-94. 1082 
In v
iew
173. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal 1083 
barrier and its breakdown in diabetic macular edema and other pathological conditions. Progress 1084 
in retinal and eye research (2013) 34:19-48. 1085 
174. Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: Cellular basis 1086 
and development. Vision research (2017) 139:123-37. 1087 
175. Caporarello N, D’Angeli F, Cambria MT, Candido S, Giallongo C, Salmeri M, et al. 1088 
Pericytes in microvessels: from “mural” function to brain and retina regeneration. International 1089 
journal of molecular sciences (2019) 20(24):6351. 1090 
176. Trost A, Bruckner D, Rivera FJ, Reitsamer HA. Pericytes in the Retina. Pericyte Biology 1091 
in Different Organs (2019):1-26. 1092 
177. Hammes H-P, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting 1093 
vasoregression. Diabetes (2011) 60(1):9-16. 1094 
178. Eshaq RS, Aldalati AM, Alexander JS, Harris NR. Diabetic retinopathy: breaking the 1095 
barrier. Pathophysiology (2017) 24(4):229-41. 1096 
179. Engerman RL, Kern TS. Hyperglycemia as a cause of diabetic retinopathy. Metabolism 1097 
(1986) 35(4):20-3. 1098 
180. Fresta CG, Fidilio A, Caruso G, Caraci F, Giblin FJ, Leggio GM, et al. A new human 1099 
blood–retinal barrier model based on endothelial cells, pericytes, and astrocytes. International 1100 
journal of molecular sciences (2020) 21(5):1636. 1101 
181. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. diabetes 1102 
(2005) 54(6):1615-25. 1103 
182. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular 1104 
endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal 1105 
disorders. New England Journal of Medicine (1994) 331(22):1480-7. 1106 
183. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic 1107 
retinopathy and VEGF. The open ophthalmology journal (2013) 7:4. 1108 
184. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene 1109 
with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes (2004) 53(3):861-1110 
4. 1111 
185. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, et al. Retinal 1112 
vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric 1113 
oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. The 1114 
American journal of pathology (2002) 160(2):501-9. 1115 
186. Roy S, Bae E, Amin S, Kim D. Extracellular matrix, gap junctions, and retinal vascular 1116 
homeostasis in diabetic retinopathy. Experimental eye research (2015) 133:58-68. 1117 
187. Pardali E, Sanchez-Duffhues G, Gomez-Puerto MC, Ten Dijke P. TGF-β-induced 1118 
endothelial-mesenchymal transition in fibrotic diseases. International journal of molecular 1119 
sciences (2017) 18(10):2157. 1120 
In rev
i w
188. Van Geest RJ, Klaassen I, Vogels IM, Van Noorden CJ, Schlingemann RO. Differential 1121 
TGF-β signaling in retinal vascular cells: a role in diabetic retinopathy? Investigative 1122 
ophthalmology & visual science (2010) 51(4):1857-65. 1123 
189. Kaur H, Chen S, Xin X, Chiu J, Khan ZA, Chakrabarti S. Diabetes-induced extracellular 1124 
matrix protein expression is mediated by transcription coactivator p300. Diabetes (2006) 1125 
55(11):3104-11. 1126 
190. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular 1127 
endothelial growth factor–mediated alterations in diabetic retinopathy. Diabetes (2011) 1128 
60(4):1314-23. 1129 
191. Campbell M, Humphries P. The blood-retina barrier.  Biology and Regulation of Blood-1130 
Tissue Barriers. Springer (2013). p. 70-84. 1131 
192. Liu L, Liu X. Roles of drug transporters in blood-retinal barrier. Drug Transporters in 1132 
Drug Disposition, Effects and Toxicity (2019):467-504. 1133 
193. Desjardins DM, Yates PW, Dahrouj M, Liu Y, Crosson CE, Ablonczy Z. Progressive early 1134 
breakdown of retinal pigment epithelium function in hyperglycemic rats. Investigative 1135 
ophthalmology & visual science (2016) 57(6):2706-13. 1136 
194. Klingeborn M, Dismuke WM, Rickman CB, Stamer WD. Roles of exosomes in the normal 1137 
and diseased eye. Progress in retinal and eye research (2017) 59:158-77. 1138 
195. Liu J, Jiang F, Jiang Y, Wang Y, Li Z, Shi X, et al. Roles of Exosomes in Ocular Diseases. 1139 
International journal of nanomedicine (2020) 15:10519. 1140 
196. Gu S, Liu Y, Zou J, Wang W, Wei T, Wang X, et al. Retinal pigment epithelial cells secrete 1141 
miR-202-5p-containing exosomes to protect against proliferative diabetic retinopathy. 1142 
Experimental eye research (2020) 201:108271. 1143 
197. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis 1144 
diseases. Biochimie (2013) 95(7):1355-9. 1145 
198. Zhang Y, Huang X-R, Wei L-H, Chung AC, Yu C-M, Lan H-Y. miR-29b as a therapeutic 1146 
agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Molecular 1147 
Therapy (2014) 22(5):974-85. 1148 
199. Zhang J, Zeng Y, Chen J, Cai D, Chen C, Zhang S, et al. miR‑29a/b cluster suppresses high 1149 
glucose‑induced endothelial‑mesenchymal transition in human retinal microvascular endothelial 1150 
cells by targeting Notch2. Experimental and therapeutic medicine (2019) 17(4):3108-16. 1151 
200. Tian D-Y, Jin X-R, Zeng X, Wang Y. Notch signaling in endothelial cells: is it the 1152 
therapeutic target for vascular neointimal hyperplasia? International journal of molecular sciences 1153 
(2017) 18(8):1615. 1154 
201. Lnsis A. Atherosclenrosis. Nature (2000) 407:233-41. 1155 
202. Wang HH, Garruti G, Liu M, Portincasa P, Wang DQ-H. Cholesterol and lipoprotein 1156 
metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Annals of 1157 
hepatology (2017) 16:S27-S42. 1158 




204. Hansson G. Inflammatory mechanisms in atherosclerosis. Journal of Thrombosis and 1161 
Haemostasis (2009) 7:328-31. 1162 
205. Ilhan F, Kalkanli ST. Atherosclerosis and the role of immune cells. World Journal of 1163 
Clinical Cases: WJCC (2015) 3(4):345. 1164 
206. La Sala L, Prattichizzo F, Ceriello A. The link between diabetes and atherosclerosis. 1165 
European journal of preventive cardiology (2019) 26(2_suppl):15-24. 1166 
207. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The 1167 
diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and 1168 
chronic inflammation. International journal of molecular sciences (2020) 21(5):1835. 1169 
208. Federici M, Lauro R. Diabetes and atherosclerosis–running on a common Road. 1170 
Alimentary pharmacology & therapeutics (2005) 22:11-5. 1171 
209. Katakami N. Mechanism of development of atherosclerosis and cardiovascular disease in 1172 
diabetes mellitus. Journal of atherosclerosis and thrombosis (2017):RV17014. 1173 
210. Reddy KJ, Singh M, Bangit JR, Batsell RR. The role of insulin resistance in the 1174 
pathogenesis of atherosclerotic cardiovascular disease: an updated review. Journal of 1175 
Cardiovascular Medicine (2010) 11(9):633-47. 1176 
211. Semenkovich CF. Insulin resistance and atherosclerosis. The Journal of clinical 1177 
investigation (2006) 116(7):1813-22. 1178 
212. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and 1179 
insulin secretion in the development of glucose intolerance. The Journal of clinical investigation 1180 
(2000) 106(3):329-33. 1181 
213. Mangiafico SP, Lim SH, Neoh S, Massinet H, Joannides CN, Proietto J, et al. A primary 1182 
defect in glucose production alone cannot induce glucose intolerance without defects in insulin 1183 
secretion. Journal of endocrinology (2011) 210(3):335. 1184 
214. Yu T, Jhun BS, Yoon Y. High-glucose stimulation increases reactive oxygen species 1185 
production through the calcium and mitogen-activated protein kinase-mediated activation of 1186 
mitochondrial fission. Antioxidants & redox signaling (2011) 14(3):425-37. 1187 
215. Vanessa Fiorentino T, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress 1188 
and its role in diabetes mellitus related cardiovascular diseases. Current pharmaceutical design 1189 
(2013) 19(32):5695-703. 1190 
216. Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New insights into oxidative stress 1191 
and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox biology (2019) 1192 
20:247-60. 1193 
217. Moreno-Viedma V, Amor M, Sarabi A, Bilban M, Staffler G, Zeyda M, et al. Common 1194 
dysregulated pathways in obese adipose tissue and atherosclerosis. Cardiovascular diabetology 1195 
(2016) 15(1):1-12. 1196 
218. Yamagishi S-i, Matsui T. Role of hyperglycemia-induced advanced glycation end product 1197 
(AGE) accumulation in atherosclerosis. Annals of vascular diseases (2018):ra. 18-00070. 1198 
In r v
i w
219. Chen P-Y, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, et al. Endothelial-to-1199 
mesenchymal transition drives atherosclerosis progression. The Journal of clinical investigation 1200 
(2015) 125(12):4514-28. 1201 
220. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman K-1202 
R, et al. Corrigendum: endothelial to mesenchymal transition is common in atherosclerotic lesions 1203 
and is associated with plaque instability. Nature communications (2017) 8. 1204 
221. Zhang H, Feng Z, Huang R, Xia Z, Xiang G, Zhang J. MicroRNA-449 suppresses 1205 
proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. 1206 
International journal of oncology (2014) 45(5):2143-52. 1207 
222. Jiang L, Hao C, Li Z, Zhang P, Wang S, Yang S, et al. miR-449a induces EndMT, promotes 1208 
the development of atherosclerosis by targeting the interaction between AdipoR2 and E-cadherin 1209 
in Lipid Rafts. Biomedicine & Pharmacotherapy (2019) 109:2293-304. 1210 
223. Vanchin B, Offringa E, Friedrich J, Brinker MG, Kiers B, Pereira AC, et al. MicroRNA‐1211 
374b induces endothelial‐to‐mesenchymal transition and early lesion formation through the 1212 
inhibition of MAPK7 signaling. The Journal of pathology (2019) 247(4):456-70. 1213 
224. Krenning G, Barauna VG, Krieger JE, Harmsen MC, Moonen J-RA. Endothelial plasticity: 1214 
shifting phenotypes through force feedback. Stem cells international (2016) 2016. 1215 
225. Nithianandarajah-Jones GN, Wilm B, Goldring CE, Müller J, Cross MJ. The role of ERK5 1216 
in endothelial cell function. Biochemical Society Transactions (2014) 42(6):1584-9. 1217 
226. Wu X, Du X, Yang Y, Liu X, Liu X, Zhang N, et al. Inhibition of miR-122 reduced 1218 
atherosclerotic lesion formation by regulating NPAS3-mediated endothelial to mesenchymal 1219 
transition. Life Sciences (2021) 265:118816. 1220 
227. Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and 1221 
its biological functions. Nature Reviews Molecular Cell Biology (2020):1-23. 1222 
228. Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J, et al. The emerging landscape of 1223 
circular RNA in life processes. RNA biology (2017) 14(8):992-9. 1224 
229. Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding 1225 
RNAs. Cancer letters (2015) 365(2):141-8. 1226 
230. Wang C, Wang L, Ding Y, Lu X, Zhang G, Yang J, et al. LncRNA structural characteristics 1227 
in epigenetic regulation. International Journal of Molecular Sciences (2017) 18(12):2659. 1228 
231. Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long 1229 
non-coding RNA. Genomics, proteomics & bioinformatics (2017) 15(3):177-86. 1230 
232. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non‐coding RNAs: regulators of 1231 
disease. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and 1232 
Ireland (2010) 220(2):126-39. 1233 
233. Chen X, Sun Y, Cai R, Wang G, Shu X, Pang W. Long noncoding RNA: multiple players 1234 
in gene expression. BMB reports (2018) 51(6):280. 1235 
234. Harries LW. Long non-coding RNAs and human disease. Biochemical Society 1236 
Transactions (2012) 40(4):902-6. 1237 
In r v
w
235. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study 1238 
of human diseases. Cancer letters (2013) 339(2):159-66. 1239 
236. DiStefano JK. The emerging role of long noncoding RNAs in human disease. Disease Gene 1240 
Identification (2018):91-110. 1241 
237. Greco S, Salgado Somoza A, Devaux Y, Martelli F. Long noncoding RNAs and cardiac 1242 
disease. Antioxidants & redox signaling (2018) 29(9):880-901. 1243 
238. He Z, Yang D, Fan X, Zhang M, Li Y, Gu X, et al. The roles and mechanisms of lncRNAs 1244 
in liver fibrosis. International journal of molecular sciences (2020) 21(4):1482. 1245 
239. Lin J, Jiang Z, Liu C, Zhou D, Song J, Liao Y, et al. Emerging Roles of Long Non-Coding 1246 
RNAs in Renal Fibrosis. Life (2020) 10(8):131. 1247 
240. Li J, Cao L-T, Liu H-H, Yin X-D, Wang J. Long non coding RNA H19: An emerging 1248 
therapeutic target in fibrosing diseases. Autoimmunity (2020) 53(1):1-7. 1249 
241. Biswas S, Thomas AA, Chakrabarti S. LncRNAs: proverbial genomic “junk” or key 1250 
epigenetic regulators during cardiac fibrosis in diabetes? Frontiers in cardiovascular medicine 1251 
(2018) 5:28. 1252 
242. Shi S, Song L, Yu H, Feng S, He J, Liu Y, et al. Knockdown of LncRNA-H19 Ameliorates 1253 
Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT. Frontiers in 1254 
Pharmacology (2020) 11:1936. 1255 
243. Thomas AA, Biswas S, Feng B, Chen S, Gonder J, Chakrabarti S. lncRNA H19 prevents 1256 
endothelial–mesenchymal transition in diabetic retinopathy. Diabetologia (2019) 62(3):517-30. 1257 
244. He Y, Dan Y, Gao X, Huang L, Lv H, Chen J. DNMT1-mediated lncRNA MEG3 1258 
methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the 1259 
PI3K/AKT/mTOR signaling pathway. American Journal of Physiology-Endocrinology and 1260 
Metabolism (2020). 1261 
245. Maghbooli Z, Hossein‐nezhad A, Larijani B, Amini M, Keshtkar A. Global DNA 1262 
methylation as a possible biomarker for diabetic retinopathy. Diabetes/metabolism research and 1263 
reviews (2015) 31(2):183-9. 1264 
246. Su Q, Sun Y, Ye Z, Yang H, Li L. Oxidized low density lipoprotein induces endothelial-1265 
to-mesenchymal transition by stabilizing snail in human aortic endothelial cells. Biomedicine & 1266 
Pharmacotherapy (2018) 106:1720-6. 1267 
247. Wu H, Liu T, Hou H. Knockdown of LINC00657 inhibits ox-LDL-induced endothelial cell 1268 
injury by regulating miR-30c-5p/Wnt7b/β-catenin. Molecular and Cellular Biochemistry (2020) 1269 
472(1):145-55. 1270 
248. Luc K, Schramm-Luc A, Guzik T, Mikolajczyk T. Oxidative stress and inflammatory 1271 
markers in prediabetes and diabetes. J Physiol Pharmacol (2019) 70:809-24. 1272 
249. Grieco GE, Brusco N, Licata G, Nigi L, Formichi C, Dotta F, et al. Targeting microRNAs 1273 
as a therapeutic strategy to reduce oxidative stress in diabetes. International journal of molecular 1274 
sciences (2019) 20(24):6358. 1275 
I r v
ie
250. Qadir MMF, Klein D, Álvarez-Cubela S, Domínguez-Bendala J, Pastori RL. The role of 1276 
microRNAs in diabetes-related oxidative stress. International journal of molecular sciences 1277 
(2019) 20(21):5423. 1278 
251. Guo Y, Li P, Bledsoe G, Yang Z-R, Chao L, Chao J. Kallistatin inhibits TGF-β-induced 1279 
endothelial–mesenchymal transition by differential regulation of microRNA-21 and eNOS 1280 
expression. Experimental cell research (2015) 337(1):103-10. 1281 
252. La Sala L, Mrakic-Sposta S, Tagliabue E, Prattichizzo F, Micheloni S, Sangalli E, et al. 1282 
Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high 1283 
risk of developing diabetes and in drug-naïve T2D. Cardiovascular diabetology (2019) 18(1):1-1284 
12. 1285 
253. La Sala L, Mrakic-Sposta S, Micheloni S, Prattichizzo F, Ceriello A. Glucose-sensing 1286 
microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose 1287 
variability. Cardiovascular diabetology (2018) 17(1):1-14. 1288 
254. Yildirim SS, Akman D, Catalucci D, Turan B. Relationship between downregulation of 1289 
miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: 1290 
junctin as a target protein of miR-1. Cell biochemistry and biophysics (2013) 67(3):1397-408. 1291 
255. Ruknarong L, Boonthongkaew C, Chuangchot N, Jumnainsong A, Leelayuwat N, Jusakul 1292 
A, et al. Vitamin C supplementation reduces expression of circulating miR-451a in subjects with 1293 
poorly controlled type 2 diabetes mellitus and high oxidative stress. PeerJ (2021) 9:e10776. 1294 
256. Srivastava SP, Kanasaki K, Goodwin JE. Loss of Mitochondrial Control Impacts Renal 1295 
Health. Frontiers in Pharmacology (2020) 11:2133. 1296 
257. Bause AS, Haigis MC. SIRT3 regulation of mitochondrial oxidative stress. Experimental 1297 
gerontology (2013) 48(7):634-9. 1298 
258. Jing E, Emanuelli B, Hirschey MD, Boucher J, Lee KY, Lombard D, et al. Sirtuin-3 (Sirt3) 1299 
regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and 1300 
reactive oxygen species production. Proceedings of the national academy of sciences (2011) 1301 
108(35):14608-13. 1302 
259. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative 1303 
stress by SIRT3-mediated SOD2 activation. Cell metabolism (2010) 12(6):662-7. 1304 
260. Cushing L, Kuang P, Lü J. The role of miR-29 in pulmonary fibrosis. Biochemistry and 1305 
Cell Biology (2015) 93(2):109-18. 1306 
261. Yang S, Banerjee S, de Freitas A, Sanders YY, Ding Q, Matalon S, et al. Participation of 1307 
miR-200 in pulmonary fibrosis. The American journal of pathology (2012) 180(2):484-93. 1308 
262. Chen Q, Qiu F, Zhou K, Matlock HG, Takahashi Y, Rajala RV, et al. Pathogenic role of 1309 
microRNA-21 in diabetic retinopathy through downregulation of PPARα. Diabetes (2017) 1310 
66(6):1671-82. 1311 
263. Jiang Q, Lyu X-M, Yuan Y, Wang L. Plasma miR-21 expression: an indicator for the 1312 
severity of Type 2 diabetes with diabetic retinopathy. Bioscience reports (2017) 37(2). 1313 
 1314 
I  r v
ew
Figure 1.JPEG
In rev
iew
Figure 2.JPEG
In rev
iew
